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Abstract 
 
Osteogenesis is a complex and still poorly understood biological 
process regulated by intrinsic cellular signals and extrinsic micro-
environmental stimuli from the surrounding stem cell-niche. Some regulators 
of osteogenesis, including growth factors and transcriptional factors,  have 
been already identified, although further studies to better elucidate the 
molecular basis of this biological process are required in order to develop new 
and more effective therapeutic strategies for the treatment of osteogenic 
diseases, such as osteoporosis, bone fractures and osteosarcoma. 
Osteoblasts arise from mesenchymal stem cells (MSCs), which are 
adult multipotent stem cells that can be successfully isolated from several adult 
and neonatal tissues, are able to generate, following appropriate stimuli, several 
differentiated mesoderm-derived cell lineages, including adipocytes, 
osteoblasts, chondrocytes and myoblasts and, therefore, represent  a promising 
cell source for regenerative medicine. 
In order to identify genes involved in the commitment of MSCs to 
osteoblasts, we performed a screening with an RNA interference-based 
approach and silenced  a large number of genes during osteoblast 
differentiation of a murine MSC-derived cell line (W20-17). With this 
procedure we identified several candidate genes potentially involved in 
osteogenesis; in fact, their silencing caused a reduction of mineralized deposits, 
as assessed by Alizarin Red staining. We then analyzed the Gene Ontology 
classification of candidate genes and we found a significant fraction (30%) of 
genes with unknown function at the time of the screening. Hence, we focused 
our attention on one of these genes that we named Osteoblasts Inducer (ObI-1), 
predicted to be a transcription factor. Indeed, Ensembl analysis showed that 
ObI-1 encodes for a protein containing several zinc-finger domains and a 
Kruppel-associated box (KRAB) domain, usually involved in transcriptional 
repression.  
We were able to observe a significant impairment in osteoblast 
differentiation, resulting in reduction of both alkaline phosphatase expression 
and mineralization, as a result of ObI-1 silencing. In addition, we evaluated 
ObI-1 expression in our cell system as well as in several mouse tissues and 
organs. Interestingly, ObI1 expression increases during osteogenic 
differentiation of both W20-17 cell line and primary murine MSCs from bone 
marrow. We demonstrated also the nuclear localization of ObI-1 through 
immunofluorescence analysis, corroborating the hypothesis that this  gene may 
encode for a transcription factor. Finally, we analyzed the effect of ObI-1 
silencing on the expression of osteogenic markers during the differentiation 
process. 
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1 – Background 
 
1.1 - Bone Tissue 
Bone tissue is a connective tissue specialized for support and trophic 
functions. Bones serve as a rigid structure to the body and as shields to protect 
delicate internal organs. Besides its structural function, bone significantly 
contributes to metabolism like a reservoir of calcium and phosphate, regulating 
homeostasis in the blood. Furthermore, bones provide a point of attachment for 
skeletal muscles and housing for the bone marrow, where the blood cells are 
formed. Intriguingly, in the last few years it has been demonstrated that bone 
could function also as an endocrine organ (Lee et al. 2007). 
Bone is composed for only 5%  of  cells whereas the largest part is 
constituted by the extracellular organic and inorganic matrix. The organic 
matrix is mainly composed of type I collagen forming fibrils, 
glycosaminoglycans, osteocalcin, bone sialo-proteins, osteopontin and 
osteonectin. The inorganic mineral matrix is constituted by hydroxyapatite, that 
is largely responsible for the strength and density of the bone, composed 
mainly of calcium and other minerals. Therefore, in order to maintain bone 
density and strength, the body requires an adequate supply of calcium, other 
minerals and vitamin D. 
All bones of the body have essentially the same structure. They present 
a compact hard outer part, called cortical bone, and a softer and less dense 
inner part, the trabecular bone; the spaces in the trabecular bone are filled by 
the bone marrow. Bones are covered by a thin membrane, the periosteum, in 
which nerves are located; blood vessels supplying blood to the bone enter 
through the periosteum.  
Bone is a dynamic and constantly changing tissue that undergoes a 
continuous process of remodeling characterized by bone resorption and 
deposition of new bone tissue (bone neoformation); indeed, every bone of the 
body is completely reformed about every 10 years. 
A characteristic of all connective tissues, including bone and cartilage, 
is that they contain a large amount of intercellular substance surrounding cells. 
There are four important types of cells associated with bone tissue: osteogenic 
cells, osteoblasts, osteocytes, and osteoclasts (Fig.1).  
- Osteogenic cells are pre-osteoblast cells derived from mesenchyme, 
which is the precursor of all forms of connective tissue. When 
osteogenic cells undergo mitosis, the resulting daughter cells can 
differentiate into osteoblasts in relation to local or systemic needs. 
- Osteoblasts  are mononucleate bone-forming cells descending from 
osteoprogenitor cells. They are fully differentiated cells that cannot 
reproduced and are responsible  for bone formation, secreting the 
organic matrix and mineral salts of the inorganic matrix. Osteoblasts 
express receptors for hormones regulating bone growth.   
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- Osteocytes are typical mature bone cells. They are osteoblasts that have 
become isolated in the intercellular substance they have deposited 
around themselves during bone neosynthesis. The spaces they occupy 
are known as lacunae. They are cells that have stopped laying down 
new bone, but they play an important role in maintaining the cellular 
activities of bone tissue in their immediate area by secreting enzymes 
and controlling the bone mineral content and the calcium release from 
the bone into the blood. Furthermore, osteocytes have been shown to 
act as mechano-sensory receptors, regulating the bone’s response to 
stress and mechanical load. 
- Osteoclasts are the cells responsible for bone resorption and play an 
important role in bone growth, healing and remodeling. They belong to 
the monocyte/macrophage cell lineage and are giant multinucleated 
cells (up to 50 nuclei per cell depending on the species) located in 
contact with calcified bone surfaces in Howship’s lacunae. Osteoclasts  
produce enzymes, such as  the tartrate resistant acid phosphatase 
secreted against the mineral substrate and express receptors for various 
hormones that regulate their activity.  
 
 
            Fig.1: Bone cell types. 
 
1.2 – Ossification 
The skeleton is a complex organ consisting of more than 200 skeletal 
elements, different for shape, size and location, composed by two distinct 
tissues, cartilage and bone. 
In mammals, bone development is the last event of skeleton 
development. During the first phase of skeletogenesis, mesenchymal cells 
aggregate at the sites where skeletal elements will develop (skeletal 
patterning); these mesenchymal condensations, prefiguring the future skeletal 
elements, are evident between 10.5 and 12.5 days postcoitum (dpc) in mouse. 
Bone formation (or ossification) can occur through two different 
mechanisms. In the skeletal elements prefiguring the clavicles and some bones 
of the skull, cells of the mesenchymal condensations differentiate directly into 
osteoblasts, that appear at 15.5 dpc of mouse development, without a cartilage 
template through a process known as intramembranous ossification (Huang et 
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al. 1997). Development of the majority of skeletal elements, instead, 
contemplate the formation of a hyaline cartilagine intermediate model of the 
bone that is eventually replaced and ossified (Fig.2). In this process, called 
endochondral ossification, cells of the mesenchymal condensations 
differentiate into chondrocytes whereas cells at the periphery differentiate into 
osteoblasts and form the perichondrium. Chondrocytes located in the center of 
mesenchymal condensations stop proliferating, become hypertrophic and start 
producing a mineral matrix rich in type X collagen. Aferwards, while 
hypertrophic chondrocytes die through apoptosis, the vascular invasion from 
the perichondrium brings in cells of the osteoblastic lineage, at about 14.5-15.5 
dpc in mouse, that differentiate into osteblasts and produce an extracellular 
matrix rich in type I collagen (Erlebacher et al. 1995). Endochondral 
ossification is the process associated with fetal bone development of long 
bones, such as the femur and humerus, day-to-day bone growth, and fracture 
repair. 
 
 
 
Fig. 2: Endochondral ossification. 
Endochondral ossification begins in points in the cartilage called primary ossification centers. 
They mostly appear during fetal development, although a few short bones begin their primary 
ossification after birth. They are responsible for the formation of the diaphyses of long bones, 
short bones and certain parts of irregular bones. Secondary ossification occurs after birth, and 
forms the epiphyses of long bones and the extremities of irregular and flat bones. The 
diaphysis and both epiphyses of a long bone are separated by a growing zone of cartilage. 
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1.3 – Bone-related pathologies 
 
1.3.1 - Bone fractures 
A fracture is defined as a partial or complete loss of continuity of the 
bone that occurs under mechanical pressure. Most fractures are caused by 
traumatic injury, however bone cancer or metabolic disorders can cause 
fractures by weakening the bone. Different bones in the body have different 
tolerance levels and capacity to endure stress. Whichever is the cause, a bone 
fracture leads to a disruption of bone architecture, laceration of the periosteum 
and breakage of bone blood vessels. 
Fractures may result in loss of function in the affected limb, guarded 
movements, pain, soft tissues swelling (edema) and deformity. They can be 
classified according to the anatomic location, the extent of the injury or the 
angle of the fracture. 
 
1.3.1.2 - Fracture repair  
Fracture repair is required to restore the normal alignment and function 
of a broken bone. Throughout the stages of fracture healing, the bone must be 
held firmly in the correct position. In the event that a fracture is not properly 
repaired, misalignment of the bone may occur, resulting in possible physical 
dysfunction of the bone. There are four phases in fracture healing: 
1. Hematoma formation: this stage is characterized by inflammation 
and the formation of a  granulation tissue. When a bone breaks it 
causes also the rupture of the blood vessels in the bone, periosteoum 
and surrounding tissues. This results, within a few hours after 
fracture, in the formation of a mass of clotted blood, or hematoma, 
at the fracture site. 
2. Fibrocartilagineous callus formation: this phase is characterized by 
the formation of a soft tissue called cartilagineous callus, necessary 
to keep the broken bones together. Capillaries grow into hematoma 
and phagocytic cells digest the cellular debris.  
3. Bone callus formation: blood vessels bring in osteoblasts that 
gradually replace the hyaline cartilage with the formation of a 
spongy bone callus.  
4. Remodeling phase: In the following weeks or months, depending on 
the location and extent of the injury, osteoblasts and osteoclasts 
continue to migrate into the site of the fracture remodeling the 
existing callus.                       
 
1.3.2 - Osteoporosis 
Osteoporosis is a chronic, systemic, metabolic disease characterized by 
loss of bone mass and disruption of the micro-architectural structure of bone 
tissue that leads to an increased risk of fracture. Osteoporosis has a 
multifactorial etiology and it can be primary, postmenopausal and senile, or 
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secondary; the underlying mechanism in all cases is an imbalance between 
bone resorption by osteoclasts and bone formation by osteoblasts during 
physiological bone remodeling. As bone resorption overwhelms bone 
formation, bones become weaker, fragile and more susceptible to fracture. The 
pathology usually affects the spongy bone of the spine, leading to compression 
fractures between vertebrae and the head of the femur.  
Estrogen has been found to play a major role in osteoporosis 
pathogenesis, since it maintains bone homeostasis  by slowing the rate of bone 
erosion. Indeed, it inhibits osteoclasts activity, and when estrogen levels 
decrease, osteoclasts activity increases to erode the bone matrix. Other factors 
contributing to osteoporosis can include an inactive lifestyle, a diet low in 
calcium an protein, or as a consequence of other diseases such as 
hyperthyroidism. 
 
1.3.3 – Osteoarthritis 
Osteoarthritis, or degenerative joint disease, refers to a set of diseases 
causing degradation of joints and represents the most common form of chronic 
arthritis. It is characterized by the degeneration of articular cartilage and the 
growth of bone tissue into the joint space; as the joint space decreases, 
movements become more difficult and painful. Osteoarthritis may occur as a 
consequence of aging and “wear and tear” on a joint over the years. 
 
1.4 – Stem cells  
Stem cells are undifferentiated cells that have the ability to self-renew 
and the potential to differentiate  into several different cell lineages in response 
to appropriate stimuli . 
Stem cells can be classified according to their origin, in embryonic 
(ESCs) and adult stem cells (ASCs), and their differentiation potential, in 
totipotent, pluripotent,  multipotent, oligopotent and unipotent stem cells. 
Totipotent stem cells, i.e. the zygote, are the most versatile stem cells in that 
they can differentiate into embryonic and extra-embryonic  tissues, giving rise 
to a complete and viable organism. Cells isolated from the inner cell mass of 
embryos at the blastocyst stage (ESCs) are pluripotent stem cells; they can 
differentiate into nearly all cell types, namely cells derived from any of the 
three germ layers, mesoderm, endoderm and ectoderm, but they are not able to 
differentiate into extra-embryonic tissues.  Multipotent stem cells are stem cells 
that have the potential to differentiate into a quite large number of cell types 
but usually deriving from a unique germ layer. Finally, oligopotent stem cells 
can differentiate into only a few cell types, while unipotent stem cells give rise 
to one specific cell lineage. 
More recently, an exciting new source of stem cells has been developed 
by Takahashi and Yamanaka (2006), the induced pluripotent stem (iPS) cells 
[4]. iPS cells are derived by genetic reprogramming of differentiated somatic 
cells using a cocktail of factors, originally Oct4, Sox2, Klf4 and c-Myc. They 
are regarded as a promising stem cell source for regenerative medicine, to 
11 
 
repair damaged tissues or organs, since iPS cells are pluripotent but, unlike 
ESCs, they do not pose ethical issues. Furthermore, iPSs can be established 
from the somatic cells of the patient, thereby avoiding issues of 
histhocompatibility. However, like ESCs, iPS can easily form teratomas in vivo 
and great efforts have been made in order to develop protocols that allow a 
complete and reproducible differentiation to appropriate cell lineages. 
 
1.5 - Mesenchymal stem cells  
Mesenchymal stem cells (MSCs) are adult, multipotent stem cells able 
to self-renew and generate, after appropriate stimuli, several mesodermal cell 
lineages, including adipocytes, osteoblasts, chondrocytes, myoblasts, tenocytes 
and haematopoiesis-supporting stroma. MSCs were identified by Alexander 
Friedenstein and coworkers in the 1960s. The investigators plated bone marrow 
cells at low density and identified a population of fibroblastoid, clonogenic 
plastic-adherent cells they named colony-forming unit-fibroblasts (CFU-f). 
Each colony, seeded under the kidney capsule of mice, was able to give rise in 
few weeks to fibrous tissue, bone and bone marrow; bone cells were of donor 
origin, whereas the hematopoietic tissue was of recipient origin, probably due 
to the homing of host circulating blood hematopoietic stem cells (HSCs) 
(Friedenstein et al. 1966). These data showed that in the bone marrow there is a 
population of cells distinct from hematopoietic precursors, able to generate 
bone tissue and to provide an appropriate microenvironment for HSCs homing 
and hematopoiesis. In the following years, further studies demonstrated that the 
inherently osteogenic cells discovered by Friedenstein and named osteogenic 
stem cells were actually multipotent and capable of generating not only 
osteoblasts, but also adipocytes, condrocytes and myoblasts (Prockop 1997). 
In the last few years, several studies have shown that MSCs could 
exhibit a broad degree of plasticity, since they seem to be able to differentiate 
into non-mesodermal cell types, including neural cell lineages, endothelial 
cells, hepatocytes and pancreatic progenitor cells (Phinney et al. 2005; Oswald 
et al. 2004; Moriscot et al. 2005) (Fig.3). However, there are still controversies 
regarding the true plasticity of MSCs; in fact, differentiations observed in vivo 
could be due to the fusion of MSCs with endogenous cells, whereas in vitro 
non-standardized culture conditions may lead to the selection of rare cell 
populations with greater differentiation potential. Furthermore, recent reports 
have shown that, at least in some circumstances, the ability of MSCs to 
promote in vivo tissue regeneration in response to disease or injury is unlikely 
due to their ability to differentiate, since they exhibit very low or transient 
levels of engraftment (Iso et al. 2007). These observations suggest that MSCs 
could promote tissue repair through the secretion of molecules that modify 
tissue microenvironment and stimulate the regeneration. 
Although MSCs were originally isolated from bone marrow, these cells 
are widely distributed throughout tissues, including adipose tissue, peripheral 
blood, skeletal muscle, tendon and several fetal tissues. However, several 
studies have reported that MSCs isolated from different sources are not 
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equivalent and, indeed, they show differences in many aspects, including the 
proliferation rate, the differentiation potential and the expression of some 
specific markers (Barlow et al. 2008). Therefore, further studies are required to 
better characterize MSCs populations from different sources in order to be able 
to select the most suitable ones for the specific purpose of the study as well as 
for clinical applications. 
 
 
Fig. 3: Sources and multilineage differentiation of MSCs. 
 
During the last years several techniques for MSCs isolation and culture-
expansion have been developed and MSCs have been successfully harvested 
from several tissues of multiple species; so far, bone marrow-derived MSCs 
(BM-MSCs) are the most intensely studied. The conventional isolation 
protocol, widely used for the purification of BM-MSCs, is based on the ability 
of these cells to adhere to tissue culture plates (Esposito et al. 2009). However, 
in the last years, great efforts have been made to characterize MSCs 
immunophenotype in order to identify a surface antigen panel that could be 
useful for the isolation and purification of MSCs. 
The definition of MSCs is extremely complicated as such cells 
represent a morphologically, phenotypically and functionally heterogeneous 
population of cells. For this reason, minimal criteria for the definition of human 
MSCs have been established: MSC have to be plastic-adherent, express 
CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or 
CD11b, CD79alpha or CD19 and HLA-DR surface molecules and, finally, they 
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have to be able to differentiate at least into osteoblasts, adipocytes and 
chondroblasts in vitro (Dominici et al. 2006).  
 
1.5.1 – Osteogenic differentiation of MSCs 
 Osteogenesis is a complex and not entirely elucidated biological 
process regulated by intrinsic cellular signals and extrinsic micro-
environmental stimuli from the surrounding stem cell-niche. Cells differentiate 
in a multi-step process in which the progression from one stage to the 
following is regulated by a complex network of growth factors, signaling 
molecules and hormones, and it is characterized by the activation and 
subsequent inactivation of transcription factors and the expression of bone 
specific marker genes (Fig.4).  
 
 
Fig. 4: Differentiation of MSCs towards osteoblasts. 
Regulators and markers of the different stages of osteogenic differentiation 
 
In vitro experiments have shown that osteogenesis proceeds through three 
different steps: 
? a proliferation phase, characterized by the proliferation of MSCs and 
pre-osteoblasts 
? a differentiation phase, characterized by the differentiation of 
osteoprogenitors into osteoblasts, mature cells able to produce new 
bone matrix. During this stage the cells gain the expression of bone 
specific markers, as alkaline phosphatase (ALP) 
? A final mineralization phase that represents the last step of 
osteogenesis. The osteoblasts start to produce calcium and phosphate 
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mineralized deposits and to synthesize late-phase proteins, like 
osteocalcin 
Although some determinants of osteogenesis have been already identified, 
further studies are require to better elucidate this biological process. Some of 
the most important regulators of osteogenesis, including growth factors and 
transcriptional factors, are described in this section (Fig.5). 
Transcription factors: the earliest and most specific marker of osteoblast 
differentiation is Runt-related transcription factor (Runx)-2 or Corebinding 
factor (Cbfa)-1, member of the RUNX family of transcription factors, that 
stimulates MSCs commitment towards the osteogenic lineage and inhibits 
adipogenic differentiation. Indeed, Runx2 deletion in mice results in a skeleton 
constituted only by chondrocytes and in a complete lack of bone formation due 
to absence of osteoblasts (Ducy et al. 1997; Komori et al. 1997). Runx2 also 
plays an important role in mature osteoblasts and in matrix formation and 
mineralization, regulating the expression of osteoblast-specific genes, such as 
ALP, type I collagen, osteopontin and osteocalcin. However, its function in 
later stages of differentiation is less clear since Runx2 over-expression under 
the control of type I collagen promoter results in osteopenia due to the lack of 
terminal maturation of osteoblasts (Liu W et al. 2001). 
Osterix is a zinc finger transcription factor expressed by osteoblast and 
required for endochondral and intramembranous bone formation. Osterix null 
mice show normal cartilage development but fail to develop mineralized bone 
(Nakashima et al. 2002). Osteoblast differentiation is arrested, and histological 
analysis reveals absence of trabecular bone. Furthermore, Osterix-null mice 
have reduced or absent expression  of several bone matrix proteins, such as 
osteocalcin, ALP, type I collagen and osteopontin, confirming a key role of this 
transcription regulator in the induction of osteoblast differentiation. In contrast 
to Runx2 null mice that do not form osteoblasts, osterix null mice form cells of 
the osteoblastic lineage expressing Runx2, but these cells fail to mature.  
The Msh family of homeobox genes includes three transcription factors: 
Msx 1, 2, and 3. Msx 3 is expressed in the central nervous system while Msx 1 
and 2 are expressed in skeletal tissue and modulate osteogenesis. Msx 2 null 
mice show defects in skull ossification, enhanced in double Msx1/Msx2 
mutants, and impaired chondrogenesis and osteogenesis due to a decreased 
number of osteoprogenitor cells (Satokata et al. 2000). The skeletal 
abnormalities are associated with a decreased expression of Runx2 indicating 
that Msx 2 is necessary for osteogenesis and acts upstream of Runx2. 
Furthermore, Msx2 could play a role also in late differentiation events since it 
is able to repress the transcription  of osteocalcin, a marker expressed late in 
osteoblast differentiation, binding directly its promoter (Dodig et al. 1999). 
The mammalian homolog of Drosophila Distalless (Dlx)-5 is an 
homeobox gene essential for  craniofacial  and skeletal development. Indeed, 
targeted gene inactivation of Dlx5 results in severe skeletal abnormalities, 
whereas Runx2 expression is unaltered (Robledo et al. 2002). Dlx5 mRNA is 
expressed in osteoblasts after differentiation, concomitant with a decline in 
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Msx2 mRNA and with the apperance of osteocalcin transcript, and it is able to 
induce the expression of ALP and osteocalcin and thereby the mineralization of 
the extracellular matrix (Miyama et al. 1999).  
Growth Factors: Bone morphogenetic proteins (BMPs) are members of the 
Transforming Growth Factor (TGF) family of polypeptides (Wozney et al. 
1988) and were originally identified for their ability to induce endochondral 
bone formation.  
To date, around 20 BMP family members have been identified and 
characterized. BMPs signal explicates through serine/threonine kinase 
receptors, composed of type I and type II subtypes. After ligand binding they 
form a heterotetrameric-activated receptor complex and interact with SMAD 
proteins, that play a key role in the signal transduction from the receptor to 
target genes in the nucleus. Furthermore, BMPs can activate SMAD-
independent pathways, such as Ras/MAPK pathway (Fig.5). BMPs are able to 
increase commitment of bone marrow mesenchymal stem cells to osteoblasts 
phenotype by increasing Runx2 mRNA expression (Lee et al. 2002). 
Wnt proteins are signalling proteins  that act on target cells by binding 
to Frizzleds (Fzs), sevenspan transmembrane receptor proteins, and LRP-5/6, 
single span transmembrane co-receptor proteins. Wnt pathway is involved in 
BMPs-mediated osteogenesis (Chen et al. 2007), and is able to induce the 
osteoblastic transcription factors Runx2, Dlx-5, and Osterix, indicating that this 
pathway is intimately associated with bone regenerative process. 
 
1.5.2 - MSCs: advantages and applications 
MSCs are considered a promising source for cell-based therapy and 
regenerative medicine, since they can be extensively expanded in vitro 
retaining their undifferentiated phenotype and differentiation potential, they do 
not cause teratoma formation in vivo and are well-tolerated in clinical trials. 
Moreover, they show unique features that largely contribute to their 
attractiveness: MSCs are immune-privileged, have the ability to migrate to 
injured tissues after systemic administration, produce several trophic factors 
and are able to regulate inflammatory and immune responses. For these reasons 
MSCs were largely employed in preclinical and clinical studies to treat a broad 
spectrum of diseases, including auto-immune and inflammatory diseases, graft 
versus host disease, myocardial infarction and spinal cord injuries (Ren et al. 
2012).  
The MSCs potential to differentiate into several cell types has opened a 
variety of tissue engineering applications. In fact, undifferentiated or 
differentiated MSCs seeded into a variety of natural or synthetic biomaterial 
scaffolds have been successfully applied in repair of cartilage and bone defects 
(Ren et al. 2012; Savarino et al. 2007). 
 Most interestingly, MSCs and their derived cell lines represent a valid 
in vitro differentiation system and a valuable tool for the identification of the 
molecular mechanisms underlying cellular differentiation; the identification of 
genes that regulate osteoblast differentiation, for instance, can directly provide 
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new pharmacological targets for the induction of bone neosynthesis and, 
therefore, the treatment of bone-related pathologies, such as osteoporosis and 
bone fractures. 
 
 
 
Fig.5: Signalling and transcription factors regulation in osteogenic differentiation. 
BMP and Wnt pathways induce osteogenic differentiation through the up-regulation of some 
osteo-specific transcription factors such as Runx2, Osterix, Dlx5 and Msx2. 
 
Recently a number of automated procedures for cell culture and 
manipulation have been developed (high-throughput screenings, HTS) making 
it possible to conduct a large number of tests with reduced manpower and more 
affordable costs. These screenings allow the identification of genes involved in 
a number of biological processes or compounds able to alter them. Recently, 
RNA interference-based approaches have become particularly popular for their 
ability to silence specific genes and, therefore, study the effect of the absence 
of a single gene product  in a particular biological phenomenon. In addition 
HTS can be used to screen compounds libraries to directly identify chemical 
compounds able to induce or block a biological process in order to discover 
potential drugs. 
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1.6 – RNA Interference 
RNA interference (RNAi) is a form of post-transcriptional gene 
silencing mediated by little double- strand molecules of RNA able to block the 
translation of mRNA targets.  RNAi is a natural process preserved during 
evolution and it is involved in several mechanisms such as the defense against 
viral infections, gene expression regulation, protection against genome 
instability and developmental regulation. RNAi can be activated by a double 
strand of RNA brought into the cell (small interfering RNA, siRNA) that leads 
to the degradation of mRNA target, or by micro RNA (miRNAs), small non 
codifying transcripts synthesized within the cell; in this case not always the 
mRNA target is degraded through  cleavage. 
miRNAs are small conserved single-strand RNA molecules of about 20-22 
nucleotides which negatively modulate gene expression primarily through base 
paring to the 3’ untranslated region (UTR) of target mRNAs; this leads to 
mRNA cleavage and/or translation repression. miRNAs are involved in 
regulation of  a variety of biological processes, such as cell proliferation, 
apoptosis and stress responses. Furthermore, miRNAs have been implicated in 
cancer, where they can act as tumor suppressors or oncogenes. Their 
biogenesis starts in the nucleus: miRNAs are first synthesized from their 
corresponding genes as longer precursors called primary miRNA (pri-
miRNAs).  Pri-miRNAs are processed by Drosha RNA polymerase III that 
generates molecules of 70-80 nucleotides with a stem and loop structure, 
known as precursor miRNAs (pre-miRNAs). Pre-miRNAs are translocated 
from nucleus to cytoplasm by a complex of receptors on the nuclear 
membrane, such as exportin 5 (Lund et al. 2004), and processed in miRNAs by 
Dicer, a ribonucleasic enzyme of the RNA polymerase III family. Each 
miRNA binds the enzymatic complex RNA-interference silencing complex 
(RISC), forming a RNA-protein complex named miRISC. Small RNA 
molecules are then separated: the sense strand is degraded while the antisense 
strand is driven towards the mRNA target by a RISC complex subunit, 
Argonauta 2 (Ago2) (Liu J et al., 2004). If miRNA and mRNA target strands 
are highly complementary, mRNA is cleaved, if they are partly mismatched, 
RISC complex linked to mRNA does not allow the translation; in both cases no 
protein is made. 
siRNAs are short molecules of double-strand RNA of 21-23 nucleotides with 
two phosphate groups at 5’ and 2 nucleotides 3’ protruding generated by Dicer. 
They can be introduced into the cells by both transfection and infection. The 
antisense strand binds the RISC complex forming the RNA-protein complex 
siRISC which recognizes the mRNA target and cleaves it.  
shRNAs (short hairpin RNA) are small RNAs with a stem and loop structure: 
they mimic the pre-miRNA structure and therefore follow their same 
processing. shRNA are expressed by plasmids or viral vectors and for this 
reason they present the advantage to perform a stable silencing of their mRNA 
targets.  
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1.6.1 - Off-target effects 
Off-target effects are defined as the consequences of not desired 
interactions between RNA interference molecules and cellular components or 
no target mRNAs and can be classified in sequence-independent and sequence-
dependent effects. 
Sequence-independent effects include the transfection conditions and 
the inhibition of the activity of endogenous miRNAs that may be caused by 
RNA-interference machinery saturation, for example the saturation of exportin 
5 (Yi et al. 2005).  
Among the sequence-dependent effects there are immune response 
stimulation and interaction with no mRNA targets. The immune response can 
be provoked by type I interferons when siRNAs  are longer than 30 base pairs 
or by the recognition of single or double strand RNA molecules by Toll-like 
receptors (TLRs). It is possible to reduce the interferon-mediated response 
avoiding the presence of some nucleotids motifs, such as GU traits, in the RNA 
sequence. However, the main cause of sequence-dependent effects is the 
interaction between RNA interference effectors and no target mRNAs; in order 
to overcome this issue it is fundamental that the RNA-interference molecule 
has the minimal homology with mRNA sequences other than its target. In 
addition, it is recommended to perform redundancy or phenotype rescue 
experiments. In redundancy experiments different effectors having the same 
mRNA target are employed. In this way, the probability that at least two 
different effectors with distinct sequences  share the same sequence-dependent 
off target effects is minor. In phenotype rescue experiments it is used a 
functional version of the target gene resistant to RNA interference effector.  
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2 – Aims of the study 
 
The aim of my study was the identification and characterization of 
novel determinants of osteogenic differentiation. Indeed, a better understanding 
of the molecular process that drive the differentiation of MSCs towards the 
osteogenic lineage  is essential to identify new molecular targets and develop 
novel and more effective therapeutic strategies for the treatment of bone-
related pathologies, such as osteoporosis, bone fractures and osteosarcoma. 
In particular, I focused my attention on the study of a novel potential 
transcription factor, that we named Osteoblasts Inducer (ObI)-1, necessary for 
MSC differentiation into osteoblasts in vitro. Therefore, we performed 
experiments aimed at the characterization of ObI-1 function in osteogenesis as 
well as at the identification of the molecular  pathways in which it is involved. 
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3 – Materials and Methods 
3.1 – Mouse shRNA library 
shRNA library (Open Biosystems, Thermo Scientific, Waltham, MA, 
USA) consists in 64.000 bacterial stocks (PirPlus competent bacteria) 
containing plasmid DNA expressing shRNA constructs that cover the entire 
mouse transcriptome. Bacterial stocks are stored in single wells in 96 well 
plates in glycerol stock at -80° C.  
The plasmid DNA is pShag Magic Version 2.0 (pSM2) retroviral vector 
(Open Biosystems). This plasmid contains the following features (Fig.6): 1) 
Murine Stem Cell Virus (MSCV) backbone with Retroviral Signaling 
Sequences; 2) U6 promoter; 3) RK6γ conditional origin of replication. It 
requires the expression of Pir1 gene within the bacterial host to propagate; 4) 
Kanamycine and Chloramphenicol resistance as bacterial selection markers; 5) 
Puromycine resistance for selection after transfection in mammalian cells; 6) 
Sequence encoding the shRNA construct.  
 
 
Fig.6 : pShag Magic Version 2.0 features. 
Structure and functional elements of the DNA plasmid of the mouse shRNA library.  
 
3.2 – Cells and culture conditions 
W20-17 cell line was purchased from American Type Culture 
Collection (ATCC/LGC standards, Teddington, UK), primary murine MSCs 
(mMSCs) were isolated from C57Bl/6 mice’s bone marrow in our laboratory 
(Esposito et al. 2009). Cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (D-MEM, Euroclone, Pero, Italy) supplemented with 10% fetal 
bovine serum (FBS, HyClone, Thermo Scientific) and 2 mM L-glutamine 
(Gibco, Life Technologies, Carlsbad, CA, USA) in absence of antibiotics.  
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3.2.1 – Osteogenic differentiation 
Cells were grown until they reached 70%-90% confluence and then 
cultured for 18 days (mMSCs) or 21 days (W20-17) in D-MEM supplemented 
with 10% FBS, 2 mM L-glutamine, 0.05 mM ascorbic acid 2-phosphate 
(Sigma-Aldrich, St. Louis, MO, USA), 10 mM glycerol 2-phosphate (Sigma-
Aldrich), 1 μM dexamethasone (Sigma-Aldrich). Medium was replaced twice a 
week. 
 
3.3 – ALP staining 
Cells were washed with cold PBS and fixed with 10% cold Neutral 
formalin buffer (NFB) for 15 min. They were incubated with the staining 
solution for 45 min. in the dark and then washed 3-4 times using distilled 
water.  
Staining solution: 
a) 5 mg Naphtol AS MX-PO4 powder (Sigma-Aldrich) in 200 μl N,N-
Dimethylformamide (Sigma-Aldrich). 
b) 25 ml 0.2 M Tris-HCl, pH 8.3  + 25 ml distilled water. 
c) 30 mg Red Violet LB salt (Sigma-Aldrich). 
Note: Prepare (a) and (b) separately; add (a) + (b); add (c). 
 
3.4 – Alizarin Red  S Staining 
 Cells were washed with PBS and fixed in 10% formaldehyde for 1 
hour. After rinsing with distilled water they were incubated with 2% Alizarin 
Red S (Sigma-Aldrich) solution with gentle agitation for 10 minutes and then 
washed 3 times with distillate water. 
 
3.4.1 - Alizarin Red S staining quantification 
Alizarin Red S solution bound to the calcium deposits of mineralized 
nodules was extracted through over-night incubation with 4M Guanidine-HCl  
(Sigma-Aldrich) at room temperature. Absorbance at 490 nm of the resulting 
supernatant was used for quantitative calcium determination. 
 
3.5 - Lipofection 
Cells were plated in the plastic support, allowed to grow until they 
reach the optimal confluence for transfection (80-90%) and then transfected  
with shRNA plasmids using Lipofectamine 2000 (Invitrogen, Life 
Technologies) according to manifacturer’s instructions. Cotransfection with a 
plasmid for the expression of a reporter gene is performed to supervise 
transfection efficiency. Two days after transfection, the cells were culture in 
selective medium containing puromycin in order to enrich for cells that 
incorporated the plasmid DNA. Puromycin amount was established on the 
basis of kill-curve experiments (3 μg/ml for W2017, 2 μg/ml for primary 
mMSCs). The medium was replaced every 2 days. A plate of untrasfected cells 
was used as a control for the enrichment. 
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3.6 – RNA extraction  
Total RNA was extracted from cells and tissues using TriReagent (Sigma-
Aldrich) according to manifacturer’s instructions.  
 
3.7 – Mice experiments 
C57Bl/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME, 
USA). All experimental procedures were conducted in accordance with 
institutional guidelines for animal care and use. Food and water were provided 
ad libitum. Mice were euthanized with carbon dioxide vapors and  organs and 
tissues were immediately collected in ice and homogenized in TriReagent.  
 
3.8 – Real Time PCR 
cDNAs were amplified from 2 μg of RNA using M-MuLV reverse 
transcriptase (New England Biolabs, Ipswich, MA, USA). RNA was incubated 
with dNTPs (Amersham Biosciences, GE Healthcare, Pittsburgh, PA, USA) 
and Random Examers (Promega, Fitchburg, WI, USA) at 70°C for 10 minutes 
and in ice for 1 minute; then, after the addition of M-MuLV and the specific 
buffer, the incubation was performed at 42°C for 1 hour followed by enzyme 
denaturation at 90°C for 10 minutes. Real time PCR was performed using the 
SYBR Green PCR master mixture in an Applied Biosystems 7900HT 
apparatus (Applied Biosystems, Foster City, CA, USA). Levels of target genes 
were quantified using specific oligonucleotide primers and normalized for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Primers 
sequences are listed in Table 1. 
 
    Table 1: Primer sequences  
Primer  Sequence (5’-3’) 
GAPDH Forward GTATGACTCCACTCACGGCAAA 
GAPDH Reverse TTCCCATTCTCGGCCTTG 
ObI-1 Forward GGTGTGGCTGGGGCACTGTTT 
ObI-1 Reverse GCTTCTGCAACACCCCACGGT 
Runx2 Forward CCTGCCATCACTGACGTGC 
Runx2 Reverse GGCCAGAGGCAGAAGTCAGA 
Osteopontin Forward GCTGGTGCCTGACCCATCT 
Osteopontin Reverse CCTTTTCTTCAGAGGACACAGGCAT 
 
 
3.9 - Construction of ObI-1 C-terminal Flag plasmid  
RNA was extracted from mouse lungs and retro-transcribed in cDNA as 
previously indicated. The following primers were used to amplified the ObI-1 
cDNA (2.043 Kb): Forward  5’-GGCCACGGGATCCAGCCATGGTGAGA 
AGACG-3’ (BamHI restriction site-containing) and Reverse 5’-
GGGCTCGCGGCCGCCAAATCCCAGA TAGGGTTTG-3’ (NotI restriction 
site-containing). For PCR amplification with Phusion Taq polymerase (New 
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England Biolabs) the following protocol was performed: 98°C for 3 minutes, 
15 cycles at 98°C for 1 minute, 49°C for 20 seconds and 72°C for 2 minutes, 5 
cycles at 98°C for 1 minute, 60°C for 20 seconds and 72°C for 2 minutes, 15 
cycles at 98°C for 1 minute  and 72°C for 2 minutes and a final extension at 
72°C for 10 minutes. The amplified product was resolved by agarose gel 
electrophoresis (1% agarose and 0.5 μg/ml ethidium bromide, Sigma-Aldrich) 
and the band was extracted using Wizard SV Gel and PCR Clean-up system 
(Promega). PCR product and pcDNA 3.1 vector (Invitrogen) were digested for 
2 hours at 37°C with BamHI and NotI (New England Biolabs), resolved by 
agarose gel electrophoresis and extracted. 
Vector dephosphorilation and  ligation reactions were performed using the 
Rapid Dephosphorilation and Ligation kit (Roche) according to manifacturer’s 
instructions. The ligation mixture was transformed into Calcium Chloride 
competent DH5α cells (Invitrogen, Life Technologies). Plasmids that after 
BamHI-NotI digestion showed the presence of a 2 Kb insert were validated by 
sequencing (Ceinge Sequencing Service). 
 
3.10 – Western Blot assays 
Total cell lysates were obtained by treatment with lysis buffer (1mM 
EDTA, 50 mM Tris-HCl, pH 7.5, 70 mM NaCl, 1% Triton X-100), protease 
inhibitors  (Complete Protease Inhibitor Cocktail, Roche, Basel, Switzerland) 
and the phosphatase inhibitors 5mM sodium fluoride and 1mM sodium 
orthovanadate (Sigma-Aldrich).  
Protein extracts were run on 10% SDS-PAGE gels, transferred on 
Immuno-Blot PVDF membranes (Bio-Rad Laboratories, Hercules, CA, USA) 
and analyzed using the following antibodies: Anti-Flag (Sigma-Aldrich, 1:500 
dilution ), Anti-GAPDH (Santa Cruz Biotechonology, Santa Cruz, CA, USA, 
1:1000 dilution) and secondary HRP-conjugated antibody (Amsterdam 
Bioscience, Uppsala, Sweden, 1:5,000 dilution). Proteins were detected by 
chemiluminescence (ECL plus, GE Healthcare). 
 
3.11 – Immunofluorescence 
mMSCs were transfected with either pcDNA 3.1 expressing ObI-1-Flag 
or empty vector using Lipofectamine 2000. After 24 hours, cells were fixed in 
4% paraformaldheyde, permeabilized with 0.2% TX-100 and blocked in 10% 
bovine serum albumin (BSA) in PBS for 30 minutes at room temperature. The 
samples were then incubated with primary murine anti-Flag antibody (1:250 
dilution) and then with an anti-mouse IgG conjugated with Alexa Fluor 488 
(Molecular Probes, Life technologies, 1/500 dilution). Both antibodies were 
diluted in 3% BSA/PBS. Cells nuclei were counterstained with 4’,6-diamidino-
2-phenylindole (DAPI) diluted 1/5,000 in PBS. Images were captured using a 
LSM 510 Meta confocal microscope (Carl Zeiss, Oberkochen, Germany).  
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4 – Results and Discussion 
4.1 – Identification of genes involved in osteoblast differentiation with a 
shRNA-based approach 
In order to identify novel genes that regulate MSCs differentiation 
towards the osteogenic lineage, we performed a screening based on an RNAi 
approach using the murine library described in materials and methods. 
W20-17 cells were plated in 96 well-plates and after one day were 
transfected with shRNA-encoding plasmids. The cells were cultured 2-3 days 
in puromycin, in order to enrich the cell population that had incorporated the 
plasmid, and then treated with osteogenic medium. After 21 days the cells were 
stained with Alizarin Red S in order to detect mineralized deposits (Fig.7). 
 
 
 Fig.7: Experimental approach to perform screening. 
Cells are plated in 96 well-plates and the day after transfected with shRNA plasmids. 
Cotransfection with a plasmid for the expression of a reporter gene is performed to supervise 
transfection efficiency. Cells are cultured for 2-3 days in presence of  puromycin and then 
treated with osteogenic medium for 21 days in order to induce osteoblast differentiation. 
 
In order to validate our experimental approach, we used several controls 
including controls of differentiation, represented by untransfected cells grown 
in osteogenic and normal medium, and a scrambled control for  the RNA 
interference technique, represented by  cells transfected with an shRNA that 
does not recognize any known murine transcript, shRNA Non Silencing 
(shRNA-NS). In  addition, as controls for the efficiency of RNAi-mediated 
block of differentiation, we included cells in which we silenced genes known 
to be involved in osteogenic differentiation, such as BMP1 and SMAD5. The 
results of Alizarin Red staining and its quantification are reported in Fig.8. 
25 
 
 
Fig.8: Experimental approach validation. 
Alizarin Red S staining after 21 day of: 1) untransfected W20-17  cells cultured in osteogenic 
differentiation; 2) untransfected cells cultured in normal medium; 3) cells transfected with 
shRNA Non Silencing and cultured in osteogenic medium; 4) cells transfected with shRNA 
SMAD5 and cultured in osteogenic medium; 5) cells transfected with a shRNA for BMP1 and 
cultured in osteogenic medium (A). Calcium deposition was quantified using 4M Guanidine 
HCl  and reading the adsorbance at 490nm. 
 
So far, we have transfected about 10,000 constructs of the library in 
single wells and we collected the relative results. Genes whose silencing 
impaired the ability of W20-17 to produce a mineralized matrix were 
considered putative candidate genes (Fig.9). Up to now, we have identified 650 
candidate genes, corresponding to 6.5% of the total number of screened genes. 
 
4.2 – In silico characterization of candidate genes 
 We performed an in silico analysis of our results using bioinformatic 
tools to obtain a Gene Ontology classification of the candidate genes 
(Carmona-Saez et al. 2007). We found candidate genes involved in signal 
transduction, transcription, transport within and between the cells, apoptosis 
and developmental processes (Fig.10).  
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Fig.9: Representative image of a plate after Alizarin Red S staining. 
Representative image of a plate as example of our screening results. Several wells do not show 
red staining: the corresponding silenced genes represent putative candidates of the screening. 
 
A remarkable result of the Gene Ontology analysis was to find a 
consistent fraction of genes (30%) with unknown function at the time of the 
screening. These genes belong to the Riken collection. In particular, we 
focused our attention on a short number of them that we named Osteoblasts 
Inducer (ObI). These genes were chosen on the basis of their putative function: 
indeed, they are predicted to be transcription factors according bioinformatic 
analysis. In my thesis project I focused on one of these potential transcription 
regulators, named ObI-1.  
 
 
Fig.10: Gene Ontology classification of screening candidate genes. 
Results of Gene Ontology classification of the candidate genes from the first part of our 
screening. Biological processes represented by more than 3% of our candidates are shown in 
the graphic. 
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4.3 – ObI-1 candidate gene 
 
4.3.1 – ObI-1 silencing impairs formation of mineralized deposits 
Among the candidate genes with unknown function, ObI-1 silencing 
with the corresponding shRNA construct of the library produced  an almost 
total absence of Alizarin Red S staining compared to the positive control of 
differentiation.  Furthermore, the effect seems to be specific for this shRNA 
since the transfection with the shRNA-NS produced the same effect of the 
positive control of differentiation (Fig.11).  
 
 
Fig.11: ObI-1 screening results. 
Alizarin Red S staining after culture in osteogenic medium for 21 days of: 1) W20-17 cells 
transfected with shRNA-ObI-1; 2) untransfected cells; 3) cells transfected with shRNA Non 
Silencing (A). Calcium deposition quantitation using Guanidine HCl 4M and adsorbance 
reading at 490 nm (B). Data are means ± SD of 3 experiments. 
 
In order to ensure the specificity of the data and to overcome off-target 
effects, we confirmed the screening results using two additional shRNA 
constructs interfering with ObI-1 gene available in the library; these shRNAs 
recognize different regions of ObI-1 mRNA, thereby minimizing the possibility 
of sequence-dependent off-target effects. Results obtained with all three 
constructs showed a significant reduction of Alizarin Red S staining (Fig.12 A-
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B). To validate the efficiency of the silencing, transcript levels of ObI-1 gene 
were evaluated by Real-Time PCR analysis. In ObI-1 silenced cells, with all 
three constructs, the levels of transcript were extremely reduced compared to 
untransfected cells and Non-Silencing transfected cells, since full match with 
the target sequence resulted in all three cases in mRNA degradation (Fig.12 C). 
These results together confirmed that the observed impairment of osteogenic 
differentiation was specifically due to ObI-1 silencing. 
 
 
 
Fig.12: Confirmation of screening results. 
Alizarin Red S staining after culture in osteogenic medium for 21 days of: 1) W20-17 cells 
transfected with shRNA-ObI-1#1 (shRNA construct used during the screening); 2-3) cells 
transfected with shRNA-ObI-1#2 and shRNA-ObI-1#3 (other two library constructs acting 
against ObI-1 gene); 4) cells transfected with shRNA-Non Silencing; 5) Untransfected (UT) 
cells (A). Calcium deposition quantitation using Guanidine HCl 4M and adsorbance reading at 
490 nm (B). Real Time PCR analysis of ObI-1 transcript levels. Data are means ± SD of 3 
experiments. 
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4.3.2 – In silico characterization of ObI-1 domains and phylogenesis   
Prior to further experimental evaluations of the role of ObI-1, we 
proceeded with an in silico analysis to better understand its structure and 
function. Analysis on Ensembl database showed two predicted transcripts for 
ObI-1: a long form and a short form (Fig.13 A). Analysis of the protein 
domains revealed that ObI-1 could encode for a  transcription factor; indeed, 
the long form presents an amino-terminal Kruppel-associated box (KRAB) 
domain, usually associated to transcriptional repression, and several zinc-finger 
domains (DNA binding domain) at the C-terminus (Fig.13 B). The short form 
instead contains only a KRAB domain  (Fig.13 C). 
The phylogenetic analysis of ObI-1 gene was also performed on 
Ensembl database in order to research orthologous genes in other species. We 
found orthologs in many species, such as  Human (Homo Sapiens), Macaque 
(Macaca mulatta), Orangutan (Pongo abelii) and Rat (Rattus Norvegicus). In 
total, 25 orthologous genes were present in the latest Ensembl  release (release 
75, February 2014), including both known and predicted protein-coding genes; 
in this last Ensembl release the human ortholog, present in previous versions, is 
missing while non-human primates orthologs are still present. Therefore, 
orthologs research was also performed using Metaphors 
(http://orthology.phylomedb.org/), a public repository of phylogeny-based 
orthology and paralogy predictions computed using resources available in 
seven different homology prediction services, and we were able to confirmed 
the presence of an human ortholog, corresponding to the known protein coding 
gene ZNF717. 
 
 
 
Fig.13: ObI-1 predicted transcripts and proteic domains. 
Bioinformatic analysis (Ensembl) of ObI-1 transcripts (A). Bioinformatic analysis to evaluate 
the presence of functional domains in ObI-1 proteins: the long form presents a KRAB domain 
and several Zinc finger domains, short form presents only a KRAB domain (B). 
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4.3.3 – ObI-1 expression in mouse 
We first performed an in silico analysis of ObI-1 expression in different 
tissues, consulting UniGene database of NCBI (National Centry of 
Biotechnology Information). The analysis of the expressed sequence tag (EST) 
profiles showed that ObI-1 is expressed in several  murine adult tissues as well 
as during embryonic development (Fig.14). 
Since EST profiles show approximate gene expression patterns and may 
not be accurate, we then performed a Real-Time PCR analysis to directly 
evaluate ObI-1expression in different mouse tissues and organs and we found 
that ObI-1 transcript is present in several tissues, including bone (Fig.15).  
 
 
 
Fig.14: In silico analysis of ObI-1 expression. 
EST profile of ObI-1 transcript in different mouse tissues and developmental stages. 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.36612). 
 
4.3.4 – Expression analysis of ObI-1 during osteogenic differentiation 
Expression analysis of ObI-1 gene in W20-17 cell line was performed 
to evaluate the presence of its transcripts during osteogenic differentiation. We 
analyzed by Real Time PCR the presence of both Obi-1 transcripts, at different 
time-points (T0, corresponding to the undifferentiated cells, and T4, T14 and 
T21). The levels of the long form of ObI-1 increase at day 4 of differentiation 
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and remain high during the whole process. The short form, instead, was almost 
undetectable, indicating that it might be either only thereotical or unrelevant in 
osteoblastic differentiation (Fig.16 A); therefore it was not further investigated. 
   
 
Fig.15: ObI-1 expression profile in tissues. 
Real Time PCR analysis of ObI-1 expression in different mouse tissues and organs. 
 
After analysis in W20-17 cell line, we also analyzed by Real Time PCR 
the expression of ObI-1 gene in primary murine mesenchymal stem cells 
(mMSC) isolated from bone marrow during osteogenic differentiation. In this 
case we evaluated only ObI-1 long transcript and we considered three different 
time points: T0, corresponding to undifferentiated cells, and T3 and T21. As 
previously reported for W20-17 cells, we detected an increase of ObI-1 
transcript levels starting from the first days of osteogenic differentiation: 
indeed, ObI-1 expression rose at day 3 and further increased at day 21 (Fig.16 
B). 
 
4.3.5 – ObI-1 silencing affects osteogenic differentiation in primary 
mMSCs 
To confirm the validity of our data, we analyzed the effects of ObI-1 
silencing also in primary mMSCs. As previously observed for W20-17 cells, 
we were able to confirm that ObI-1 silencing significantly impaired the ability 
of cells to produce mineralized nodules, as assessed by Alizarin Red S staining 
after 18 days of osteogenic induction (Fig.17 A). We also confirmed the 
silencing efficiency by evaluating ObI-1 transcript levels by Real Time PCR. 
In ObI-1 silenced cells, with two distinct constructs targeting different regions 
of ObI-1 mRNA, the levels of transcript were extremely reduced compared to 
untransfected cells and Non-Silencing transfected cells (Fig.17 B). 
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Fig.16: Expression analysis of ObI-1 during osteogenic differentiation. 
Expression profile of ObI-1 transcripts during osteogenic differentiation of W20-17 cells at day 
0, 4, 14 and 21 (A) and of mMSC cells at day 0, 3 and 21 (B). Data are means ± SD of 3 
experiments. 
 
Then, we evaluated whether the function of ObI-1 was required for the 
proper differentiation of mMSCs into osteoblasts. Indeed, by performing the 
Alizarin Red S staining, we investigated the end point of osteogenic 
differentiation, represented by the mineralized matrix production, but we were 
not able to discriminate if ObI-1 function is necessary during the first stages of 
the differentiation process, namely pre-osteoblast proliferation and subsequent 
differentiation; further experiments are required to determine whether ObI-1 
silencing resulted in a reduced mineralization as a consequence of impaired 
osteoblasts differentiation and maturation or, rather, it is involved only in the 
latter mineralization phase. Therefore, we evaluated the expression of ALP, a 
marker expressed by mature osteoblasts, by performing an ALP staining, and 
we observed that ObI-1 silencing resulted in a reduced staining (Fig.18). This 
experiment showed that ObI-1 is not involved only in the mineralization phase, 
but osteoblasts differentiation and/or proliferation of osteogenic precursors  
may be dependent on the expression of this gene. Moreover, this result is in 
agreement with the previous observation that ObI-1 is expressed early during 
osteogenic differentiation of both W20-17 and primary cells. 
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Fig.17: ObI-1 silencing effects in primary mMSCs. 
Alizarin Red S staining of mMSCs after 18 days of culture. 1-2) mMSCs transfected with 
shRNA-NS cultured, respectively, in regular and osteogenic medium; 3-4) mMSCs cells 
transfected with shRNA-ObI-1#1 and shRNA-ObI-1#2 cultured in osteogenic medium (A). 
Real Time PCR analysis of ObI-1 transcript levels (B). Data are means ± SD of 3 experiments. 
 
 
 
Fig.18: ObI-1 silencing effects on mMSCs differentiation into osteoblasts. 
ALP staining of mMSCs after 12 days of culture. 1-2) mMSCs transfected with shRNA-NS 
cultured, respectively, in regular and osteogenic medium; 3-4) mMSCs cells transfected with 
shRNA-ObI-1#1 and shRNA-ObI-1#2 cultured in osteogenic medium. 
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4.3.6 - Expression profile of osteogenic differentiation markers in ObI-1 
silenced cells 
To better investigate the role of ObI-1 during osteogenic differentiation 
we evaluated, by Real Time PCR analysis, expression profile of some 
osteogenic differentiation markers in untransfected cells and in cells 
transfected with either shObI-1 or sh-NS. In particular, we analyzed the 
expression of two markers, Runx2 and osteopontin (OPN). The transcription 
factor Runx2 is considered the master gene of osteoblastogenesis; it is an early 
marker expressed during the first days of the differentiation process and it is 
absolutely required for the commitment of MSCs towards the osteogenic 
lineage as well as for the function of mature osteoblasts. OPN, on the other 
end, is a sialoprotein of the bone matrix and its levels increase steadily 
throughout the diffentiation process  from the first days of differentiation, 
reaching a peak during the mineralization phase; therefore, OPN is considered 
also a late marker of osteoblastogenesis. We found that levels of both markers 
were significantly reduced in ObI-1 silenced cells while, in cells transfected 
with sh-NS, the expression levels were comparable to untransfected cells 
(Fig.19). 
 
 
Fig.19: Effect of ObI-1 silencing on bone differentiation marker expression. 
Expression profile of early differentiation markers in W20-17 ObI-1 silenced cells. Real Time 
PCR analysis was performed at day 4 of osteogenic differentiation and reveals a decreased 
expression of both Runx2 and osteopontin in ObI-1 silenced cells compared to untransfected 
(UT) cells and cells transfected with sh-NS. 
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4.3.7 – ObI-1 is a nuclear protein 
We performed an immunofluorescence analysis in order to evaluate the 
sub-cellular localization of the protein product of ObI-1 gene. At this aim, we 
first cloned the cDNA of ObI-1 long form in pcDNA 3.1 plasmid with a 
carboxy-terminal Flag tag since specific antibodies against ObI-1 protein were 
not available at the moment. We collected protein lysates from mMSCs 
transfected with either the ObI-1 Flag-encoding plasmid or the empty vector 24 
hours after transfection and we were able to confirm ObI-1 expression by 
Western Blot analysis (Fig.20 A). Subsequently, we performed an 
immunofluorescence analysis to assess ObI-1 protein cellular localization. 
Merge between the nuclear dye DAPI and the anti-Flag antibody indicated that 
ObI-1 localized only into the cell nucleus, thereby supporting the hypothesis 
that this gene encodes for a transcription factor; however ObI-1 seems to be 
excluded from the nucleoli (Fig.20 B). 
 
 
 
Fig.20: Analysis of ObI-1 sub-cellular localization. 
Western Blot analysis to confirmed ObI-1 expression in mMSCs transfected with pcdna 3 ObI-
1 Flag. Cells transfected with the empty vector were used as a negative control. GAPDH was 
used as control for protein loading (A). Immunofluorescence analysis indicating the nuclear 
localization of ObI-1 protein (B). 
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4.4 - Discussion 
Osteoblastogenesis is a complex and still not yet completely elucidated 
biological process regulated by several hormones, signaling molecules and 
growth factors and characterized by the activation and inactivation of 
transcription factors and by the expression of bone-specific differentiation 
markers. Great efforts have been made to characterize the factors that drive 
MSCs commitment towards the osteogenic lineage and regulate osteoblasts 
maturation and bone synthesis; however, further studies are mandatory to 
identify the molecular mechanisms underlying cellular differentiation and all 
the pathways and the molecules involved. This is of paramount importance to 
identify new targets for the development of novel therapeutic options for the 
treatment of bone-related diseases as well as to optimize the differentiation 
process and to obtain the large amount of progenitor cells needed for tissue 
engineering applications.  
To identify genes involved in this biological process, we performed a 
screening with an RNA interference-based approach and silenced a large 
number of genes during osteoblast differentiation of W20-17 cells, a murine 
MSC-derived cell line. The same library had been successfully used to identify 
genes involved in the maintenance of ESCs stemness (Parisi et al. 2008). With 
this procedures we were able to identify several genes potentially involved in 
osteogenesis since their silencing  impaired the ability of cells to produced 
mineralized deposits, as assessed by Alizarin Red staining. We decided to 
performed Alizarin Red S staining to evaluate osteogenic differentiation for 
two principal reasons: the method is quite simple, largely described and used in 
literature and gives solid and reproducible results, and it allowed us to evaluate 
the end point of differentiation and, therefore, to identify genes involved in any 
stage of the process. We also validated our experimental approach as well as 
the functionality of the shRNAs of the library including several controls, such 
as untransfected cells in culture with normal and osteo-inductive medium, cells 
transfected with shRNA-NS and shRNAs that silenced known genes involved 
in osteogenesis regulation. 
We then analyzed the Gene Ontology classification of candidate genes 
and we found a significant fraction (30%) of genes with unknown function at 
the time of the screening. Hence, we focused our attention on one of these 
genes, predicted to be a transcription factor, that we named Osteoblasts 
Inducer-1 (ObI-1). We found other constructs in the library that recognized 
ObI-1 gene and, therefore, we could perform silencing confirmation 
experiments with three different constructs; this represents a specificity control 
for the RNA interference technique. Indeed, in RNA-interference experiments, 
a molecule can cause off-target effects, independently by its activity on the 
putative mRNA target (Jackson and Linsley 2010). However, since we 
obtained the same results  with different RNA molecules interfering with the 
same gene, we could exclude off-target effects. 
We next proceeded with an in-silico analysis, particularly required for 
genes with unknown function. Ensembl analysis showed that ObI-1 encodes 
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for two potential transcripts, a long form and a short form. Interestingly, the 
long form encodes for a potential transcription factor as the protein contains 
several zinc-finger domains at C-terminus and an amino-terminal KRAB 
domain. Therefore, we hypothesized that ObI-1 could belong to the family of 
KRAB-containing zinc-finger transcription repressors. These transcription 
regulators represent the largest single family of transcription factors in 
mammals, they are present only in tetrapod vertebrates and have been involved 
in several biological processes, including cell proliferation and differentiation, 
apoptosis and neoplastic transformation (Urrutia 2003). Moreover, a recently 
identified KRAB-containing transcription factor have been involved in 
regulation of osteogenic differentiation (Jheon et al. 2001). To confirm this 
hypothesis we performed an immunofluorescence experiment aimed at the 
identification of ObI-1 sub-cellular localization and we were able to 
demonstrate the nuclear localization of the protein, reinforcing the idea that this 
gene may encode for a transcription factor. 
Proceeding with the bioinformatic analysis on Ensembl, we 
demonstrated a possible conservation of this gene: in fact we found 
orthologues in several species. It was interesting to find homologous genes in 
Human with different levels of identity with the mouse gene (the better  value 
was about 46% for one of them). However, in Ensembl last release 75 
(February 2014) the human ortholog is no longer reported. Therefore, ortholog 
research was also performed using Metaphors (http://orthology.phylomedb. 
org/), a public repository of phylogeny-based orthology and paralogy 
predictions computed combining multiple prediction methods, and we 
confirmed the presence of an human ortholog. Ortholog prediction is a 
powerful comparative genomic tool, useful for gene function prediction and 
phylogenetic analysis, and a large variety of orthologs prediction methods have 
been developed in the last few years, including the Ensembl resource 
(EnsemblCompara; Vilella et al. 2009). However, the few comparative studies 
of the quality of the different algorithms currently available show that the 
predictions are not always accurate and reliable, that often different resources 
originate different results and that some methods perform better than others 
depending on the specific task (Chen et al. 2007; Altenhoff and  Dessimoz 
2009). Moreover, orthologs prediction is not a trivial issue, particularly for 
eukaryotic genomes because of their size, the complexity of protein domain 
architecture and extensive gene duplications (Doolittle 1995; Henikoff et al. 
1997). Therefore, the results of such predictions should always be cautiously 
taken into account and, whether feaseble, complemented with experimental 
data. 
Expression analysis of ObI-1 in tissues was investigated with both in 
silico analysis and Real-Time PCR experiments after RNA extraction from 
different mouse tissues. In-silico analysis was performed by EST profiles 
research on UniGene database of NCBI. ESTs derived from automated partial 
sequencing of a library of complementary DNA (cDNA) obtained from retro-
transcription of longer mRNAs present in a specific tissue, cell types, 
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developmental stage or pathologic condition, used to construct the cDNA 
library. Therefore, an EST profile can give an approximate gene expression 
pattern of a specific gene. This analysis showed that ObI-1 is expressed in 
several tissues, including bone marrow, and during mouse development. Our 
analysis performed by Real-time PCR revealed a different distribution of ObI-1 
gene in mouse tissues and organs. For example, we found that ObI-1 is 
expressed at high levels in lung, while no expression of the gene was found in 
this organ by EST profiles analysis. Also data regarding other organs were 
different, such as the expression of ObI-1 in bone. Concerning the 
inconsistencies between the two analyses, it is important to note that the EST 
profiles evaluation, although valuable, shows only approximate gene 
expression patterns and presents some limitations. In fact, EST sequences 
might contain errors and the accuracy of the predicted expression profiles is, 
especially for low-abundant transcripts, highly dependent on the cDNA library 
dimension and prone to misrepresentation (Alba et al. 2004).  
Then, we evaluated  by Real Time PCR  the expression of ObI-1 in 
W20-17 cells. We analyzed the expression of both ObI-1 transcripts during 
osteogenic differentiation and we detected an increase in the levels of the long 
form only during the differentiation process; its levels increased from the first 
days of differentiation and remained high until the end, indicating that it could 
play a role in this process. The levels of the short form, instead, were very low, 
almost undetectable, during the all process and, therefore, it was no longer 
investigated. Indeed, this finding could indicate that either the short form is 
only theoretical or it is not involved in osteogenic regulation. Although the 
levels of ObI-1 long form significantly increased during osteogenic 
differention (5-fold increase from day 0 to day 4 of differentiation), they were 
generally quite low but seemingly sufficient to exert their effect. 
In order to complete expression analysis in cells, we also performed a 
Real Time PCR analysis in primary mMSCs isolated from mouse in our 
laboratory (Esposito et al., 2009). Analysis in primary cells was very important 
since a cell line, such as W20-17, may not exactly reproduce a physiological 
cellular environment, although it presents several advantages, as a greater 
standardization and reproducibility of the experiments and the possibility to 
extensively expand the cells in an undifferentiated state. On the other hand, 
primary cells keep the distinctive features of the native organ or tissue and 
reflect better the biochemical activities of cells in vivo compared to a cell line. 
Expression of ObI-1 gene during osteogenic differentiation of mMSCs was 
comparable to the data obtained in W20-17 cells. This finding further 
confirmed a role of our candidate in osteogenic differentiation. 
Therefore, we proceeded with the validation of ObI-1 silencing effects 
on osteogenic differentiation of primary mMSCs and, as previously reported 
for W20-17 cells, we observed a reduction in mineralized matrix synthesis, 
assessed by Alizarin Red S staining, in ObI-1 silenced cells compared to cells 
transfected with shRNA-NS.  In addition, we also observed that ObI-1 
silencing resulted in a reduced expression of ALP, a marker expressed by 
39 
 
mature osteoblasts. Thereby, we could conclude that ObI-1 plays a role not 
only in the latter mineralization stage, but its function is important also in an 
earlier phase of differentiation. This hypothesis was further corroborated by the 
observation that ObI-1 silencing caused a reduced expression, at day 4 of 
differentiation of W20-17 cells, of the osteogenic markers Runx-2 and OPN. 
Indeed, the transcription factor Runx-2 is an early marker of osteogenesis and 
it is required for the commitment of MSCs towards the osteogenic lineage; it is 
involved also in the later stages of differentiation but its role is still not clear. 
OPN, instead, is a bone sialoprotein expressed throughout osteogenic  
diffentiation, from the first days of the process. 
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5 – Conclusions 
 
In conclusion, in this work we have described the identification, 
through an RNAi-based screening, and the characterization of ObI-1, a novel 
potential transcription factor involved in the regulation of osteogenic 
differentiation of mMSCs. Indeed, ObI-1 function seems to be important for 
the proper osteoblasts maturation and bone mineral matrix deposition.  
Currently, we are investigating the potential role of ObI-1 as a 
transcription factor, its targets and the molecular pathways in which the gene is 
involved. Indeed, we are performing a microarray analysis to evaluate the 
differential gene expression in cells in which ObI-1 has been silenced 
compared to control cells. We have planned to performed also a chromatin 
immunoprecipitation assay followed by high-throughput DNA sequencing 
(ChIP-seq), in order to identify the specific DNA sequences bound by ObI-1 
and, therefore, its direct targets. These assessments, indeed, could be useful to 
better understand the role played by ObI-1 during osteogenesis as well as to 
elucidate the biological pathways in which it is involved. 
We are interested also in the better evaluation and identification of ObI-
1 human ortholog, by combining the in silico analysis with different 
bioinformatic tools and experimental data. To accomplish this goal, for 
instance, we could take advantage of microarray and ChIP-seq data; indeed, the 
identification of ObI-1 targets and molecular pathways could be useful to 
identify the human protein that plays an analogous role. 
We are also planning to analyze the expression profile of additional 
osteogenic markers in ObI-1 silenced cells as well as to investigate the 
potential involvement of this gene in regulating other differentiation processes. 
Finally,  we would like to examine ObI-1 function in- vivo, using a 
knock-out or a conditional knock-out mouse model. In this way, we could 
better understand not only the role of our candidate gene in osteogenesis but 
also its involvement in other biological  processes. 
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Osteosarcoma is a highly metastatic tumor affecting adolescents, for which there is no second-line chemothera-
py. As suggested for most tumors, its capability to overgrow is probably driven by cancer stem cells (CSCs), and
ﬁnding new targets to kill CSCsmay be critical for improving patient survival. TP53 is themost frequentlymutat-
ed tumor suppressor gene in cancers and mutant p53 protein (mutp53) can acquire gain of function (GOF)
strongly contributing tomalignancy. Studies thus far have not shown p53-GOF in osteosarcoma. Here, we inves-
tigated TP53 gene status/role in 3AB-OS cells—a highly aggressive CSC line previously selected from human oste-
osarcoma MG63 cells—to evaluate its involvement in promoting proliferation, invasiveness, resistance to
apoptosis and stemness. By RT-PCR, methylation-speciﬁc PCR, ﬂuorescent in situ hybridization, DNA sequence,
western blot and immunoﬂuorescence analyses, we have shown that—in comparison with parental MG63 cells
where TP53 gene is hypermethylated, rearranged and in single copy—in 3AB-OS cells, TP53 is unmethylated,
rearranged and inmultiple copies, andmutp53 (p53-R248W/P72R) is post-translationallymodiﬁed andwith nu-
clear localization. p53-R248W/P72R-knockdown by short-interfering RNA reduced the growth and replication
rate of 3AB-OS cells, markedly increasing cell cycle inhibitor levels and sensitized 3AB-OS cells to TRAIL-
induced apoptosis byDR5 up-regulation;moreover, it strongly decreased the levels of stemness and invasiveness
genes.Wehave also found that the ectopic expression of p53-R248W/P72R inMG63 cells promoted cancer stem-
like features, as high proliferation rate, sphere formation, clonogenic growth, highmigration and invasive ability;
furthermore, it strongly increased the levels of stemness proteins. Overall, the ﬁndings suggest the involvement
of p53-R248W/P72R at the origin of the aberrant characters of the 3AB-OS cells with the hypothesis that its GOF
can be at the root of the dedifferentiation of MG63 cells into CSCs.
© 2013 Elsevier Inc. All rights reserved.
Introduction
Osteosarcoma (OS), the most common malignant bone tumor in
adolescents and young adults, is a highly aggressive tumor exhibiting
clinical, histologic and molecular heterogeneity [1]. The current stan-
dard chemotherapy regimen, which includes cisplatin, doxorubicin
andmethotrexate, provides only 65–70% long-term disease-free surviv-
al for OS patients without metastasis [2], and there is no established
second-line chemotherapy for relapsed OS; thus, the identiﬁcation of
new therapeutic strategies to improve the clinical outcome of these
patients is urgent.
It is well known that most solid tumors contain a distinct subpopu-
lation of cancer stem cells (CSCs), which represent the source for tissue
renewal, hold malignant potential and can be responsible for therapy
resistance [3–6], and it has been suggested that a successful cure of
cancer should requires eradication of CSCs [7–9].
Previously, we have demonstrated that the short-term treatment of
human OS MG63 cells with 3-aminobenzamide (3AB), a potent inhibi-
tor of the chromatin remodelling enzymepoly(ADP-ribose)polymerase,
inducedmorphological and biochemical features of osteocyte differenti-
ation, accompanied by the down-regulation of gene products required
for proliferation and the up-regulation of those implicated in osteoblast
differentiation [10]. However, prolonged treatment (about 100 days) of
MG63cellswith3AB inducedosteocyte death accompaniedbyprogressive
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enrichment of a new heterogeneous and stable cell population termed
3AB-OS [11], which have properties (self-renewal and pluripotency
in vitro, tumorigenicity in vivo) that indicated them as CSCs [12,13] and
allowed their patenting. 3AB-OS cells have been characterized at genetic
and molecular level: compared to parental MG63 cells, which have a
hypotriploid karyotype with chromosome number ranging from 61 to
66, they are hypertriploid with chromosome number ranging from
71 to 82; they also exhibit 49 copy number variations (gains/losses)
spanning almost all the chromosomes, 3,512 dysregulated genes and
189 differentially expressed miRNAs. Moreover, bioinformatic analyses
selected 196 genes and 46 anticorrelated miRNAs involved in carcino-
genesis and stemness [14]. Remarkably, the abnormalities evidenced
in 3AB-OS cells appear to be strongly congruent with abnormalities
described in a large number of pediatric and adult OS patients, where
karyotype ranging from haploid to near hexaploid with chromosome
number ranging from 15 to 120 were described; in addition, a great
number of chromosomal regions with structural abnormalities among
which 17p11.2–13 that contains TP53 gene were found [15–17].
It is known that TP53mutations occur in almost every type of cancer
and often mutant p53 proteins (mutp53) express gain of function
(GOF), which can enhance the ability of cancer cells to invade and me-
tastasize, confer resistance to chemotherapies, promote genomic insta-
bility and drivemultinucleation [18–27]. Recently, evidence linking p53
loss to stem-like phenotype in cancer has been reported [28]; however,
how p53 contributes to acquisition of “stemness” at themolecular level
andwhether stem-like cells confer survival advantages to propagate the
tumor remains to be resolved. Here, we investigated TP53 gene status
and role in 3AB-OS cells. We demonstrated that in 3AB-OS cells, p53 is
mutated (p53-R248W/P72R) and displays GOF activity. Furthermore,
we showed that the ectopic expression of p53-R248W/P72R promoted
cancer stem-like properties in osteosarcoma MG63 parental cells. The
results suggest p53-R248W/P72R as a key regulator at the origin of
the aggressiveness, chemoresistance and stemness of human 3AB-OS
CSCs.
Materials and methods
Cell cultures
Human osteosarcoma MG63 cells were acquired from Interlab Cell
Line Collection (ICLC, Genova, Italy). The human 3AB-OS cancer stem
cells have beenproduced in our laboratory [11] and patented (Pluripotent
cancer stem cells: their preparation and use. Renza Vento and Riccardo
Di Fiore, Patent Appln. No. FI2008A000238, December 11, 2008). Cell
lines were cultured as monolayers in T-75 ﬂask in Dulbecco's modiﬁed
Eagle medium (DMEM), supplemented with 10% (v/v) heat-inactivated
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and
50 μg/ml streptomycin (Euroclone, Pero, Italy) in a humidiﬁed atmo-
sphere of 5% CO2 in air at 37 °C. When cells grew to approximately 80%
conﬂuence, they were subcultured or harvested using 0.025% trypsin–
EDTA (Life Technologies Ltd, Monza, Italy).
Morphological observation
Cell morphology was evaluated using a Leica DM IRB inverted micro-
scope (LeicaMicrosystems Srl,Milano, Italy). Imageswere photographed
and captured by a computer-imaging system (Leica DC300F camera and
Adobe Photoshop for image analysis).
RT-PCR analysis for p53
RNA was isolated using RNeasy mini kit (Qiagen, Milano, Italy).
cDNA was ampliﬁed from 1 μg of RNA as previously reported [29]
followed by polymerase chain reaction (PCR). The reactions omitting
reverse transcriptase enzyme served as negative control. GAPDH was
used as a housekeeping gene to demonstrate equal loading of RNA.
The ampliﬁed products were resolved by agarose gel electrophoresis
(1% agarose, 0.5 μg/ml ethidium bromide; Sigma-Aldrich), and the
bands were visualized and photographed with Chemi Doc XRS (Bio-
Rad Laboratories Srl, Segrate (MI), Italy). The primer sequences (Proligo
USA, Milan, Italy) are as follows: TP53 (432 bp), forward 5′-GGGACAGC
CAAGTCTGTG-3′ and reverse 5′-GGAGTCTTCCAGTGTGAT-3′; GAPDH
(200 bp), forward 5′-TGACATCAAGAAGGTGA-3′ and reverse 5′-TCCA
CCACCCTGTTGCTGTA-3′. For PCR analysis, the following protocol was
performed: 95 °C for 5 min, 30 cycles at 95 °C for 1 min, 54 °C for
1 min, 72 °C for 1 min and a ﬁnal extension at 72 °C for 10 min.
Cell genomic DNA extraction, sodium bisulﬁte genomic treatment and TP53
methylation-speciﬁc PCR (MS-PCR)
Genomic DNA was extracted from cultured cells using QIAamp
DNAMini Kit (Qiagen) following themanufacturer's instructions. Geno-
mic DNA was bisulﬁte treated using an EpiTect Bisulﬁte Kit (Qiagen).
The treatment of genomic DNA with sodium bisulﬁte converts
unmethylated, but not methylated cytosines, into uracil, producing
sequence differences between methylated and unmethylated DNA.
Two micrograms of DNA were modiﬁed in 40 μl of water with sodium
bisulﬁte following the manufacturer's instructions. After bisulﬁte
modiﬁcation, PCR on the CpG island of the TP53 promoter was per-
formed with the unmethylation-speciﬁc primers (U): 5′-TTAGTATTTA
TGGTATTAGGTTGGT-3′ and 5′-AACAAATAATCCACCTACCAA-3′, and
methylation-speciﬁc primers (M): 5′-GTATTTACGGTATTAGGTCGGC-3′
and 5′-AAATAATCCGCCTACCGA-3′, using 5U of AmpliTaq polymerase
(Applied Biosystems, Foster City, CA) and the following PCR conditions:
95 °C for 5 min, 35 cycles of 95 °C for 30 s, 51 °C for 45 s and 72 °C for
60 s and a ﬁnal 8 min at 72 °C. A methylated and bisulﬁte converted
human control DNA (EpiTect PCR control DNA; Qiagen) was used as a
positive control. Each PCR product was analyzed by electrophoresis on
2% agarose gel. Gel images were visualized and photographed with
Chemi Doc XRS (Bio-Rad Laboratories Srl, Segrate (MI), Italy).
TP53 ﬂuorescent in situ hybridization (FISH) analysis
FISH analyses were performed on MG63 and 3AB-OS cells by
Toma Advanced Biomedical Assays S.p.A. (Busto Arsizio (VA), Italy)
with p53 (17p13)/SE 17 probe (Kreatech Diagnostics, Amsterdam,
The Netherlands), containing the p53 tumor suppressor gene-speciﬁc
region and the chromosome 17 Satellite control probe. These analyses
were performed following the manufacturer's protocol and analyzing
50 nuclei and 10 metaphases (1000× magniﬁcation).
DNA sequence analysis of p53 exons 1–11
DNA sequence analyses were performed on MG63 and 3AB-OS cells
by BioRep S.r.l. (Milano, Italy). Genomic DNA was extracted from cul-
tured cells using QIAamp DNA Mini Kit (Qiagen) following the
manufacturer's instructions. PCR reactions were carried out under stan-
dard conditions with primer sets speciﬁc for the coding exons 1–11 of
the TP53 gene reported in Supplementary Table 1. PCR products were
puriﬁed using ExoSAP (Amersham Biosciences Italia, Milano, Italy)
treatment and sequenced with the DYE-namic ET Dye Terminator
Cycle Sequencing Kit (Amersham Biosciences Italia). Sequencing reac-
tions were puriﬁed using the Montage SEQ96 Cleanup Kit (Millipore
S.p.a., Milano, Italy), and sequencing runs were performed on the
MegaBACE 500 DNA Analysis System (Amersham Biosciences Italia).
Immunoﬂuorescence Staining for p53
The cells were ﬁxed with 3.7% formaldehyde for 10 min at room
temperature and permeabilized with 0.1% Triton® X-100 (all from
Sigma) in phosphate-buffered saline (PBS) for 5 min. After washing
with PBS, cells were incubated with anti-p53 primary antibody (diluted
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1:100 in PBS + 1% BSA + 0.05% NaN3; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 4 °C, overnight. Cells were washed three times
with PBS and incubated for 1 h at room temperature with Cy3-
or Cy2-conjugated secondary antibody (diluted 1:100 in PBS + 1%
BSA + 0.05% NaN3; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA). Nuclei were counterstained with 2.5 μg/ml Hoechst
33342 (Sigma-Aldrich) for 10 min. After threewashes, cellswere exam-
ined on a Leica DM IRB invertedmicroscope equippedwith ﬂuorescence
optics and suitable ﬁlters for DAPI, FITC and rhodamine detection;
images were photographed and captured by a computer-imaging sys-
tem (Leica DC300F camera and Adobe Photoshop for image analysis).
Transient down-regulation of p53 by short interfering RNA (siRNA)
Cells were plated in a six-well plate format and cultured in DMEM
medium, supplemented with 10% FBS, for 24 h to reach approximately
60–80% conﬂuence. Speciﬁc siRNAs directed against p53, obtained by
St Cruz Biotechnology as a pool of double-stranded RNA oligonucleo-
tides, were transfected for 5 h into the cells at a ﬁnal concentration of
50 nM, in the presence of 5 μl Metafectene Pro (Biontex, Martinsried/
Planegg, GmBH, Munich, Germany) in a ﬁnal volume of 1 ml serum-
free DMEM. At the end, the reaction was stopped replacing the culture
medium with DMEM + 10% FBS. Cells were examined for p53 down-
regulation and other properties 24–72 h after transfection. siRNA,
consisting in a scramble sequence, was used as a negative control.
Growth curve and cell viability assays
Total cell number and viabilitywere evaluated by Trypan blue exclu-
sion counting. Brieﬂy, cells were harvested every 24 h and resuspended
in PBS. Aliquots of cell suspensions were diluted with 0.4% trypan blue
(Sigma-Aldrich Srl, Milano, Italy), pipetted onto a hemocytometer and
counted under a microscope at 100× magniﬁcation. Live cells excluded
the dye, whereas dead cells admitted the dye intensely staining with
trypan blue. The number of viable cells for each experimental condition
was counted and represented on a linear graph. Doubling time (DT)was
estimated by the following equation: DT = (t2 − t1) ln2 / lnX2 / X1,
where X2 and X1 are the number of cells at t2 and t1.
EdU in corporation assay
For EdU (5-ethynyl-2′-deoxyuridine) incorporation experiments,
cells were incubated with 10 μM EdU (Click-iT™ EdU Alexa Fluor
High-Throughput Imaging Assay, Invitrogen, Life Technologies Ltd,
Monza, Italy) for 2 h. Cells were then washed with PBS, ﬁxed with
3.7% formaldehyde for 15 min at room temperature and permeabilized
with 0.5% Triton X-100 (all from Sigma) in PBS for 20 min. After exten-
sive washingwith 3% bovine serum albumin (BSA) in PBS, incorporated
EdU was detected by ﬂuorescent-azide coupling reaction (Click-iT,
Invitrogen). Brieﬂy, cells were incubated for 30 min with azide-
conjugated Alexa Fluor 488 dye in TBS supplemented with 4 mM
CuSO4. Cells were then washed three times with 3% BSA in PBS. Nuclei
were counterstained with 2.5 μg/ml Hoechst 33342 (Sigma-Aldrich),
for 10 min. After threewashes, cellswere examined by ﬂuorescencemi-
croscopy using ﬁlters for DAPI and FITC. The percentage of EdU-positive
nuclei was determined by counting ﬁve random high-powered ﬁelds
(400×).
Cell death assays
Apoptotic morphology was studied in cells stained with Hoechst
33342 (Sigma-Aldrich). In particular, cells were stained with Hoechst
33342 (2.5 μg/ml medium) for 30 min at 37 °C, visualized by ﬂuores-
cence microscopy using an appropriate ﬁlter for DAPI; images were
photographed and captured. Cells were evaluated on the basis of their
nuclear morphology, noting the presence of homogeneous chromatin,
condensed chromatin, and fragmented nuclei.
Apoptosis was also studied by ﬂow cytometry of either DNA content
or annexin V labelling. For DNA staining, trypsinized cell suspensions
were centrifuged, washed 3 times with PBS and resuspended at 1 ×
106 cells/ml in PBS. Cells were mixed with cold absolute ethanol and
stored for 1 h at 4 °C. After centrifugation, cells were rinsed 3 times in
PBS, and the pellet was suspended in 1 ml of propidium iodide (PI)
staining solution (3.8 mM sodium citrate, 25 μg/ml PI, 10 μg/ml RNase
A; Sigma-Aldrich Srl, Milano, Italy) and kept in the dark at 4 °C for 3 h
prior to ﬂow cytometry analysis. The proportion of cells giving ﬂuores-
cence in the sub-G0/G1 peak of cell cycle was taken as a measure of
apoptosis.
For annexinV labelling, trypsinized cell suspensionswere centrifuged,
washed 3 times with PBS and resuspended in 1× annexin V binding
buffer (BD Biosciences Pharmingen, San Diego, CA) at a concentration
of 1 × 106 cells/ml. One hundred microliters of cell suspension was
then incubated with 5 μL of annexin V-FITC (BD Biosciences) and 5 μL
of PI for 15 min at a room temperature in the dark. Double labeled
with annexin V and PI allows a distinction of early apoptotic (annexin
V+/PI−) and late apoptotic/necrotic (annexin V+/PI+) cells. Flow cytom-
etry analyses were performed by a COULTER EPICS XL ﬂow cytometer
(Beckman Coulter Srl, Cassina De Pecchi (MI), Italy) equipped with a
single Argon ion laser (emission wavelength of 488 nm) and Expo 32
software. The green ﬂuorescence was measured in the FL1 channel
using a 515-nm BP ﬁlter, and the red ﬂuorescence was measured in the
FL3 channel using a 620-nm BP ﬁlter. At least 1 × 104 cells per sample
were analyzed and data were stored in list mode ﬁles.
Measurement of mitochondrial transmembrane potential (Δψm)
Mitochondrial membrane potential was measured by the cationic
lipophilic ﬂuorochrome 3,3-dihexyloxacarbocyanine (DiOC6 Molecular
Probes, Eugene, OR), which exclusively emits within the spectrum of
green light. Loss in DiOC6 staining indicates disruption of themitochon-
drial inner transmembrane potential (ΔΨm). Cells were incubatedwith
40 nM DiOC6 for 20 min at 37˚C, washed twice with PBS and analysed
by ﬂow cytometry. The green ﬂuorescence was measured as above
described.
In vitro matrigel invasion assay
Invasion assays were performed using 6-well invasion chamber sys-
tem (BD Biosciences, Discovery Labware, Becton Dickinson, Buccinasco,
Italy). Cells were trypsinized and counted with a hemocytometer using
trypan blue, and viable cells were seeded in the upper chamber at 1 ×
105 cells/well in serum-free DMEM. DMEM supplemented with 10%
FBS (used as a chemoattractant) was placed in the bottomwell. Incuba-
tion was carried out for 48 h at 37 °C in humidiﬁed air with 5% CO2.
Nonmigratory cells in the upper chamber were then removed with a
cotton-tip applicator. Migrated cells on the lower surface were stained
with Hoechst 33342 (2.5 μg/ml; Sigma-Aldrich) for 10 min and then
visualized under an inverted microscope. The number of migrating
cells was determined by counting ﬁve high-powered ﬁelds (200×) on
each membrane. Four independent experiments were performed in
triplicate.
Construction of expression vector expressing p53 mutation
(p53-R248W/P72R) and stable transfection
RNA from 3AB-OS cell line was isolated using TRI Reagent (Sigma-
Aldrich), according to manufacturer's instructions. cDNAwas ampliﬁed
from 2 μg of RNA using M-MuLV reverse transcriptase (New England
Biolabs, Euroclone, Pero, Italy). The following protocol was performed:
RNA was incubated with dNTPs (Amersham Biosciences) and Random
Examers (Promega Italia Srl, Milano, Italy) at 70 °C for 10 min and in
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ice for 1 min; then, after the addition ofM-MuLV and the speciﬁc buffer,
the incubation was performed at 42 °C for 1 h and at 90 °C for 10 min.
The following primerswere used to ampliﬁed TP53 (≈1.2 kb): forward
(BamHI restriction site-containing) 5′-CGTAGGATCCAGCCATGGAGGA
GCCGCAG-3′ and reverse (XhoI restriction site-containig) 5′-CGGATC
TCGAGCAATTCAGTCTGAGTCAGGCC-3′. For PCR ampliﬁcation with
Phusion Taq polymerase (New England Biolabs), the following protocol
was performed: 98 °C for 2 min; 12 cycles at 98 °C for 10 s, 63 °C for
20 s and 72 °C for 30 s; 18 cycles at 98 °C for 10 s and 72 °C for 30 s;
a ﬁnal extension at 72 °C for 7 min. The ampliﬁed product was resolved
by agarose gel electrophoresis (1% agarose and 0.5 μg/ml ethidium bro-
mide; Sigma-Aldrich) and the band was extracted using Wizard SV Gel
and PCR Clean-up system (Promega Italia Srl). PCR product and pcDNA
3.1 vector (Invitrogen) were digested for 2 h at 37 °C with BamHI-HF
and XhoI (New England Biolabs), resolved by agarose gel electrophore-
sis and extracted. Vector dephosphorylation and ligation reactionswere
performed using the Rapid Dephosphorylation and Ligation kit (Roche,
Milano, Italy) according to manufacturer's instructions. The ligation
mixture was transformed into calcium chloride-competent DH5α cells
(Invitrogen). Plasmids after BamHI–XhoI digestion that showed the
presence of a 1.2-kb insert were validated by sequencing (Ceinge
Sequencing Service, Ceinge, Napoli, Italy).
MG63 cells were plated in 6-well dishes until they reached 90%
conﬂuence and then transfected with p53-R248W/P72R-pcDNA 3.1 or
empty vector, as a control, using Lipofectamine 2000 (Invitrogen)
according to manufacturer's instructions. Two days after transfections,
the cells were transferred in 100 mm dishes in selective medium con-
taining 300 μg/ml G418 (Gibco, Life Technologies Ltd, Monza, Italy);
the medium was replaced every 3–4 days. A plate of untrasfected cells
was used as a control for the selection.
Sarcosphere formation assay
MG63 cells transfected with pcDNA3.1-p53-R248W/P72R or empty
pcDNA3.1 vector were seeded in 6-well ultra-low attachment plates
(Corning Costar, Euroclone) at a density of 500 cells/well with 3 ml
stem cell medium consisting of DMEM/F12 (Gibco), B27 (1× Gibco),
recombinant human epidermal growth factor (rhEGF, 20 ng/ml; Sigma-
Aldrich) and basic ﬁbroblast growth factor (bFGF, 20 ng/ml; Sigma-
Aldrich). The stem cell medium was changed every 3 days, and cells
were observed every day by microscopy. After the primary spheres
reached approximately ≥50 μm in diameter (determined using
the ImageJ software), they were collected by gentle centrifugation
(800 rpm), enzymatically dissociated (10 min at 37 °C in 0.05%
trypsin–EDTA; Life Technologies Ltd) to single cells and replanted
into 6-well ultra-low attachment plates with 500 cells/well and cultured
with stem cell medium to generate spheres of the next generation.
Colony formation assay
MG63 cells transfected with pcDNA3.1-p53-R248W/P72R or empty
pcDNA3.1 vector were seeded in 6-well plates at a density of 100
cells/well with 3 ml culture medium and incubated for 10 days. The
medium was changed every 3 days, and cells were observed every
day by microscopy. On the tenth day, media was removed from the
wells and washed once with ice-cold PBS. The colonies were ﬁxed
with 50% EtOH and stained with 1% methylene blue (Sigma-Aldrich)
for 10 min. After three washes with PBS, the colonies consisting of
N50 cells were counted using microscopy. Colony size was determined
by measuring the area with the ImageJ software.
Scratch/wound-healing assay
To analyze cell migration by wound healing, conﬂuent monolayers
of MG63 cells transfected with pcDNA3.1-p53-R248W/P72R or empty
pcDNA3.1 vector and cultured in 6-well plates were scratched with a
200-μl pipette tip to generate the wound. One hour before scratching,
the medium was replaced with medium containing 0.1% FBS to mini-
mize the cell proliferation. Phase-contrast photographs of the same
region were taken with the same magniﬁcation (100×) at 0, 8 and
24 h post-wounding. The extent of wound closure was determined by
measuring with the ImageJ software the area of cells that migrated
into the wound and then dividing by the total area of wound.
Flow cytometry analysis of CD133, ABCG2 and p53 expression
Cells were detached using 0.025% trypsin–EDTA in PBS, counted and
washed in 0.1% BSA in PBS at 4 °C. At least 500,000 cells (in 100 μl PBS/
0.5% BSA) were incubated with ﬂuorescent-labelled monoclonal anti-
bodies or respective isotype controls (1/10 diluted 4 °C for 30 min
in the dark). After washing steps, the labelled cells were analyzed
by ﬂow cytometry using COULTER EPICS XL (Beckman-Coulter Srl)
and Expo 32 software. The antibodies used were mouse anti-human
CD133/2 PE conjugated (Miltenyi Biotec S.r.l., Bologna, Italy), mouse
anti-human ABCG2 nonconjugated (Santa Cruz Biotechnology) and
mouse anti-human p53 nonconjugated (Santa Cruz Biotechnology).
For indirect labelling, cells were incubated with a compatible secondary
antibody FITC conjugated (Santa Cruz Biotechnology, Inc.). For intracel-
lular staining of CD133, ABCG2 and p53, cells were processed using the
Caltag Fix & Perm Kit (Invitrogen) following the manufacturer's guide-
lines. The green ﬂuorescence was measured as described in the Cell
death assays section, and the phycoerythrin ﬂuorescencewasmeasured
in the FL2 channel using a 575-nm BP ﬁlter. At least 1 × 104 cells per
sample were analyzed, and data were stored in list mode ﬁles. The ex-
pression of cell markers was determined by comparison with isotype
control.
Cell cycle and proliferation analyses
Cell cycle phase distribution was studied by ﬂow cytometry of DNA
content. This method was described in the Cell death assays section.
The proliferation index was calculated as the sum of cells in S and
G2/M phases of cell cycle [30].
RNA extraction and real-time RT-PCR
RNA was extracted by Trizol reagent (Life Technologies Ltd, Monza,
Italy); a DNase I treatment step was included. One microgram of total
RNAwas reverse transcribed in aﬁnal volume of 20 μl reverse transcrip-
tion (RT) by using a Super-Script First-Strand Synthesis kit for RT-PCR
(Life Technologies Ltd) according to the manufacturer's instructions.
The resulting cDNAs were used for quantitative analysis by real-time
PCR (qPCR) using the primers (Proligo, Milan, Italy) reported in Supple-
mentary Table 2 and the Power SYBR Green PCR Master Mix (Applied
Biosystem,Warrington, UK). Reactionswere performed in 48-well plates
according to manufacturer's instructions, using Applied Biosystems
StepOneTM instrument. Each reaction mixture contained 2 μl of tem-
plate cDNA, 12.5 μl of SYBR Green PCR Master Mix 2X, a ﬁnal concentra-
tion of 300 nMof forward and reverse primers and RNase-free dH2O to a
ﬁnal volume of 25 μl. qPCRs were performed in triplicate and repeated
for conﬁrmation. PCR cycling was performed as follows: 95 °C for
10 min, 95 °C for 30 s, 60 °C for 60 s, 72 °C for 30 s for 40 cycles and a
ﬁnal extension at 72 °C for 5 min. To determine primer speciﬁcity,
three stages (95 °C for 15 s, 60 °C for 20 s and 95 °C for 15 s, with a
ramping time of 20 min) were added at the end of the PCR to obtain
dissociation curves for each gene. To verify that the RT-PCR signals
derived from RNA rather than genomic DNA, for each gene tested a
control identical to the test assay but omitting the RT reaction (no RT
control) was included. qPCR data were analyzed by SDS 2.1 software.
Relative transcript levels were determined using the 2−ΔΔCt method
and normalized to endogenous β-actin control.
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Western blot analysis
Cells were washed in PBS and incubated on ice-cold lysis buffer
(RIPA buffer 50 μl/106 cells) containing protease inhibitor cocktail
(Sigma-Aldrich) for 30 min and sonicated three times for 10 s.
Equivalent amounts of proteins (40 μg) were separated by SDS–
polyacrylamide gel electrophoresis and transferred to a nitrocellu-
lose membrane (Bio-Rad) for detection with primary antibodies
and the appropriate horseradish peroxidase–conjugated secondary
antibodies. Immunoreactive signals were detected using enhanced
chemiluminescence (ECL) reagents (Bio-Rad). The correct protein
loading was conﬁrmed by stripping the immunoblot and reprobing
with primary antibody for actin (diluted 1:500; Sigma). Bands were
visualized and photographed with Chemi Doc XRS (Bio-Rad). Quan-
tiﬁcation was performed using Quantity One software, and the data
(relative density normalized to actin) were expressed as mean ± SD
of four experiments. The primary antibodies are provided in Supple-
mentary Table 3.
Statistical Analysis
Data, represented as mean ± SD, were analyzed using the 2-tailed
Student t-test usingMicrosoft Excel. Differenceswere considered signif-
icant when P b 0.05.
Results
p53 gene and protein status in MG63 and 3AB-OS cells
At ﬁrst, we examined by RT-PCR analysis the expression of TP53
mRNA in both 3AB-OS and MG63 parental cells. We detected mRNA
transcript for TP53 in 3AB-OS cells but not in MG63 cells (Fig. 1A).
Because a low or unmeasurable level of TP53 gene expression may be
correlated with promoter hypermethylation [31–34], we also evaluated
the methylation status of the TP53 promoter by MSP in both cell lines.
As it can be seen in Fig. 1B, in 3AB-OS cells, the promoter was found
unmethylated, while MG63 cells showed an aberrant TP53 promoter
methylation status.
To determine the chromosome 17 (chr17) and TP53 copy numbers,
MG63 and 3AB-OS cells were hybridized using a dual-color direct
labelled probe speciﬁc for chr17 α-satellite and for TP53 gene region.
We have analyzed interphase (INT) andmetaphase (MET) nuclei show-
ing (Fig. 1C) that both cell lines exhibit alterations of chr17 and TP53
gene; MG63 cells show chr17 trisomy and one TP53 signal which did
not colocalize with chr17, whereas 3AB-OS cells show chr17 tetrasomy
with three and four TP53 signals, someofwhich colocalizingwith chr17.
We also sequenced the coding exons 1–11 of TP53 gene in both 3AB-
OS and MG63 cells. As shown in Fig. 1D, 3AB-OS cells evidenced alter-
ations in the exons 4 and 7. More precisely, codon 72 CCC was altered
into CGC in the sequence orientation (p53Ex4s), and from GGG into
Fig. 1. Analysis of p53 gene and protein in MG63 and 3AB-OS cells. (A) Expression of TP53 mRNA detected by reverse transcriptase polymerase chain reaction (RT-PCR). GAPDH was
ampliﬁed to conﬁrm the quality and quantity of mRNA from each cell line. (B) Methylation-speciﬁc PCR of TP53. Primer sets used for ampliﬁcation are designated as unmethylated (U)
andmethylated (M). A sample containing DNA-freewater andmastermix solutionwas used as negative control (NC); a methylated and bisulﬁte converted human control DNA, designed
as +C, was used as a positive control. (C) FISH analyses of the TP53 gene (17p13) performed using a p53-speciﬁc DNA probe (red ﬂuorescent signals), simultaneously hybridized with a
chromosome 17-centromeric probe (green ﬂuorescent signals). Analyses were performed on interphase (INT) and metaphase (MET) nuclei. The scale bar represents 5 μm (D) DNA
sequence analysis of the TP53 exons 4 and 7 in 3AB-OS cells. (E) Western blot analysis of both p53 and its phosphorylated (p) and acetylated (ac) forms. Actin was used as the internal
control. Images are representative of four independent experiments. (F) Immunoﬂuorescence analysis of p53 in 3AB-OS cells, by double staining cells with both Hoechst 33342 dye (blue,
left panel) to localize thenucleus, and anti-p53 antibody and Cy3-conjugated secondary antibody (red,middle panel) to localize p53. In the right panel, themerge of the two dyes is shown.
The scale bar represents 25 μm. Images are representative of four independent experiments.
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GCG on the reverse strand (p53Ex4r). This transversion produced an
amino acid substitution of arginine for proline (P72R), a common poly-
morphism of TP53 gene. Fig. 1D also shows that codon 248 CGG was
altered into TGG in the sequence orientation (p53Ex7s), and from GCC
into ACC on the reverse strand (p53Ex7r). This transition produced an
amino acid substitution of tryptophan for arginine (R248W) that affects
p53 DNA binding ability. Since sequencing reactions of both strands
conﬁrmed the presence of only the altered nucleotide, we noticed that
the mutations were indeed homozygously present in 3AB-OS cells.
No alterations were detectable in the exons of MG63 cells (data not
shown).
Given the results obtained above, we have examined the expression
of mutp53 (p53-R248W/P72R) by western blot analysis. As shown in
Fig. 1E, the protein was detected in 3AB-OS cells while it was not
found inMG63 cells.Wehave also analyzed the post-translational phos-
phorylation and acetylation status of the protein. As shown in Fig. 1E,
the p53-R248W/P72R protein resulted phosphorylated at Ser15 and
acetylated at Lys320 and Lys373-382; furthermore, immunoﬂuores-
cence analysis (Fig. 1F) evidenced that in 3AB-OS cells, it exhibited a nu-
clear localization. Overall, these results demonstrated that in 3AB-OS
cells, TP53 gene is mutated and that p53-R248W/P72R is stabilized
and has nuclear localization.
Study of gain of function of p53-R248W/P72R in 3AB-OS cells
Aimed at evaluating whether, in 3AB-OS cells, p53-R248W/P72R
has acquired GOF activities (enhanced cell proliferation, invasiveness
and resistance to apoptosis), we have depleted the protein by small-
interfering RNA (siRNA). To this purpose, 3AB-OS cells were transfected
with p53-siRNA or a scrambled siRNA (Scr-siRNA). Then, ﬁrst, we
checked the effects of the p53-targeting siRNA on the level of endoge-
nous protein. At 24–72 h after transfection, the content of the protein
was assessed by western blot (Fig. 2A) and immunoﬂuorescence
(Fig. 2B) analyses. Both the analyses showed that after 24–72 h of
p53-siRNA transfection, p53-R248W/P72R level potently lowered. The
effects were observed at 24 h after transfection and peaked at 48 h
when more than 70% reduction in the content of the protein was ob-
served. Thereafter, p53-R248W/P72R levels markedly went up, so that
at 72 h after transfection, we only observed a 22% reduction in its
level. This suggested that, at that time, the transient silencing was in
rapid recovery. Overall, the results suggested that the optimal silencing
efﬁciency was reached at 48 h after transfection. The knockdown of
the protein was speciﬁc as no protein reduction was observed in cells
transfected with Scr-siRNA.
p53-R248W/P72R-knockdown inhibits 3AB-OS cell proliferation
To evaluate whether p53-R248W/P72R-knockdown modiﬁed the
growth of 3AB-OS cells, untransfected cells and cells transfected with
Scr-siRNA or with p53 siRNA were microscopically observed and
analysed (0–72 h) for cell number, percentage of cells in the S-phase
of cell cycle (EdU incorporation) and percentage of viability. In Fig. 3A,
the image obtained by phase contrast microscopy shows that upon
knockdown of p53-R248W/P72R, in comparison to untransfected or
Scr-siRNA-transfected cells, cell number lowered. The results were
in accordance with the trend of the p53-R248W/P72R protein level ob-
served after p53siRNA transfection. Fig. 3B also shows that p53-R248W/
P72R depletion reduced the growth rate and the replication rate of 3AB-
OS cells, whereas it did not induce loss of cell viability. Also, the speed of
cell growth and replication reﬂected the trend of p53-R248W/P72R-
knockdown. There was no statistically signiﬁcant difference between
untransfected cells and cells transfected with Scr-siRNA. These results
well agreed with microscopy analysis. Next, we examined the expres-
sion of a number of cell cycle-related proteins and genes at 48 h post-
transfection. In Fig. 3C, western blot and real-time PCR analyses showed
that the p53-R248W/P72R-knockdownmarkedly increased the levels of
pRb, p130, p107, E2F1, E2F4, GADD45, p21 and p27, whereas it potently
decreased CDK4 levels. No alteration in the expression of cyclins and
other CDKs was observed (data not shown).
p53-R248W/P72R-knockdown reduces resistance to TRAIL-induced
apoptosis and regulates Bcl-2 family members and mitochondrial
membrane potential
We have previously demonstrated that 3AB-OS cells express low
levels of the death receptors FAS and DR4 [14] and show strong resis-
tance to TRAIL (TNF-related apoptosis inducing ligand) (effects evaluat-
ed using TRAIL concentrations up to 100 ng/ml, unpublished data).
Here, we evaluated whether the p53-R248W/P72R-knockdown mod-
iﬁes the expression levels of DR4 (TRAIL-R1), KILLER/DR5 (TRAIL-R2)
and FAS/CD95 at 48 h post-transfection. In Fig. 4A, western blot analy-
ses show that p53-R248W/P72R depletion signiﬁcantly increased
protein expression levels of DR4 and DR5, whereas it did not change
FAS level. Thus, to evaluate TRAIL sensitivity, untransfected cells and
cells transfected for 24 h with Scr-siRNA or p53-siRNA were treated
with TRAIL (40 ng/ml) for 36 h. In Fig. 4B, phase contrast microscopy
shows that TRAIL markedly reduced cell number also inducing apopto-
sis in p53-silenced cells, as suggested by the presence of round-shaped
cells ﬂoating in the medium, membrane blebbing and apoptotic body
formation. As chromatin condensation and nuclear fragmentation re-
main the hallmarks of apoptotic cells, apoptosis was assessed by stain-
ing nucleic acid with Hoechst 33342. As shown Fig. 4B, in p53-siRNA-
transfected cells, TRAIL induced typical apoptotic nuclei, exhibiting
highly ﬂuorescent condensed and fragmented chromatin. Apoptosis
was also studied by ﬂow cytometry of either DNA content or annexin
V labelling. Fig. 4C shows that treatment with TRAIL resulted in 29% of
cells accumulation in sub-G0–G1 phase with a 20% of early apoptotic
cells (annexin V+/PI−) in p53-siRNA-transfected cells. The effects
of TRAIL were also evidenced in both untransfected and Scr-siRNA-
transfected cells, but these effects were much less pronounced than in
p53-siRNA-transfected cells. Collectively, these results demonstrate
that p53-R248W/P72R-knockdown sensitizes 3AB-OS cells to TRAIL-
induced apoptosis. We also investigated by cytoﬂuorimetric analysis
if p53-R248W/P72R can attenuate mitochondrial apoptosis signal-
ling pathways. DiOC6 staining revealed that the p53-R248W/P72R-
knockdown induced a signiﬁcant decrease in ﬂuorochrome uptake,
indicating a loss of Δψm (Fig. 4D). To further dissect the molecules in-
volved in the mechanism, we investigated whether the p53-R248W/
P72R-knockdown modiﬁes the expression levels of both anti-apoptotic
(Bcl-2 and Bcl-XL) and pro-apoptotic (Bax and Puma) factors. In
Figs. 4E and 4F, real-time PCR and western blot analyses showed that
the p53-R248W/P72R-knockdown signiﬁcantly decreased Bcl-2 and
Bcl-XL levels while it increased Bax and Puma levels. These results well
agreed with those obtained by cytoﬂuorimetric analysis.
p53-R248W/P72R shows the gain-of-function properties involved in
promotion of cell invasiveness
To evaluatewhether p53-R248W/P72R-knockdown inﬂuences 3AB-
OS cells invasiveness, we performedMatrigel invasion transwell assays.
As shown in Fig. 5A, p53-siRNA transfection potently decreased (−80%)
the invasive capability of 3AB-OS cells, whereas no statistically sig-
niﬁcant difference was observed in untransfected and Scr-siRNA-
transfected cells. We also examined the expression of a number of
cell invasion-related genes and proteins at 48 h post-transfection. In
Figs. 5B and 5C, real-time PCR and western blot analyses showed that
p53-R248W/P72R-knockdown signiﬁcantly decreased the levels of
the invasive proteins matrix metalloproteinases 2 and 9 (MMP2 and
MMP9), integrin alfa5 (ITGα5) and integrin alfaV (ITGαV) while it
increased the levels of the cell adhesion protein E-Cadherin, without
altering the expression of proteins involved inmesenchymal phenotype
(N-cadherin, β-catenin and vimentin).
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Fig. 2.Evaluation of knockdown efﬁciency of p53-R248W/P72R. 3AB-OS cellswere transfectedwith scrambled siRNA (Scr-siRNA) or p53-siRNAand analyzed at 24–72 h after transfection.
(A) Western blot analysis of p53-R248W/P72R and densitometric analysis of protein bands. Data (relative density normalized to actin) represent the mean with standard deviation
(n = 4); *P b 0.05 and **P b 0.01 as compared to Scr-siRNA-transfected cells. (B) Immunoﬂuorescence analysis by double staining cells with both Hoechst33342 dye (blue) to localize
the nucleus and anti-p53 antibody and Cy3-conjugated secondary antibody (red) to localize p53. The scale bar represents 25 μm. Images are representative of four independent
experiments.
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p53-R248W/P72R-knockdown affects the expression of stem-cell markers
Previously, we have shown that 3AB-OS cells express a large number
of genes required for maintaining stemness [11] and that theymorpho-
logically and functionally transdifferentiate in vitro into cells of all
three primary germ layers (ectoderm, endoderm and mesoderm) [12].
We also demonstrated that stemness markers were profoundly down-
regulated in differentiated cells. Here we have shown (Fig. 6A) that
undifferentiated 3AB-OS cells strongly expressed p53-R248W/P72R
while it profoundly lowered in derived cell lineages.We also investigated
whether p53-R248W/P72R-knockdown affected the expression of the
most important stemness markers (Oct3/4, Nanog, Sox2, nucleostemin
(NS) and CD133) that exhibited very high levels in untransfected 3AB-
OS cells. In Figs. 6B and 6C, western blot and real-time PCR analyses
showed that p53-R248W/P72R-knockdown potently decreased the
levels of all the analysed pluripotency markers.
Fig. 3. Effect of p53-R248W/P72R-knockdown on growth advantage of 3AB-OS cells. (A) Inverted phase contrast microscopy at 0–72 h after transfection. The scale bar represents 100 μm.
Images are representative of four independent experiments. (B) Analysis of total cell number (a), percentage of cells in the S-phase of cell cycle (b) by EdU incorporation and percentage of
cell viability (c). The data represent themeanwith standard deviation (n = 4); *P b 0.05 and **P b 0.01 as compared to Scr-siRNA-transfected cells. (C) Analyses of cell-cycle regulators at
48 h after silencing.Western blot analysis (a) and quantiﬁcation of protein bands by densitometric analysis (b) and real-time PCR (c). Data (relative density normalized to actin) represent
the mean with standard deviation (n = 4); *P b 0.05 as compared to Scr-siRNA-transfected cells. Data represent the mean with standard deviation (n = 4); *P b 0.05 and #P b 0.005 as
compared to Scr-siRNA-transfected cells.
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Ectopic expression of p53-R248W/P72R promotes cancer stem-like
properties in osteosarcoma MG63 cells
The above-described ﬁndings suggest that the GOF property of
p53-R248W/P72R could be at the root of 3AB-OS stemness. To evaluate
such a hypothesis, ﬁrst—as reported in materials and methods—we
produced a pcDNA3.1-vector containing p53-R248W/P72R; then, we
stably transfected MG63 cells with either empty pcDNA3.1 vector or
pcDNA3.1-p53-R248W/P72R. MG63 cells transfected with pcDNA3.1-
p53-R248W/P72R were designated R248W/P72R cells, while MG63
cells transfected with empty pcDNA3.1 vector were designated vector
cells. Selected cells were then used to evaluate p53-R248W/P72R pro-
tein expression and localization. Western blot analysis (Fig. 7A) shows
that, as expected, p53 protein was not detectable in vector cells, while
it was expressed in R248W/P72R cells; in addition, ﬂow cytometry anal-
ysis (Fig. 7B) shows a strong positivity for p53 (N75%) in R248W/P72R
cells. Immunoﬂuorescence analysis shows the nuclear localization of
p53 protein in R248W/P72R cells (Fig. 7C).
Thereafter, we evaluated in vitrowhether p53-R248W/P72R expres-
sion in MG63 cells promotes cancer stem-like features, as high prolifer-
ation rate, sphere formation, clonogenic growth, high migration and
invasive ability [35]. Initially, we compared the growth curves of
R248W/P72R cells and vector cells. As shown in Fig. 7D, with respect
to vector cells, R248W/P72R cells possess a higher proliferative output,
exhibiting a doubling time of approximately 25 h, whereas vector
cells show a doubling time of 33 h. This was conﬁrmed by DNA content
proﬁles—revealed byﬂowcytometry analysis of propidium iodide stained
cells—showing that R248W/P72R cells weremostly in the S-G2\M phase,
while vector cells were predominantly in G0\G1 (Fig. 7E).
It has been reported that cancer stem-like cells can be cultured in
suspension to generate ﬂoating spheroid-like bodies under serum-free
medium with bFGF and EGF [36]. Thus, we tested sarcosphere-
forming ability of R248W/P72R cells compared to vector cells. Fig. 7F
shows that both vector and R248W/P72R cells were capable of forming
sarcospheres. In particular, after 5 days in culture, vector cells formed
sarcospheres having a mean diameter of 60.2 ± 5.7 μm, at a frequency
of approximately 1/54 (9.3 ± 1.5 spheres/500 cells),while R248W/P72R
cells formed larger sarcospheres (mean diameter of 68.7 ± 7.6 μm) at a
frequency of approximately 1/42 (12 ± 2.0 spheres/500 cells). After
10 days, R248W/P72R sarcospheres increased in size and number,
having a mean diameter of 110 ± 23 μm and containing about 576
cells/sphere. Even vector sarcospheres increased in size and number,
Fig. 4. Effect of p53-R248W/P72R-knockdown on: DR4, DR5 and FAS receptors, TRAIL-induced apoptosis, mitochondrial membrane potential and Bcl-2 family members. (A)Western blot
analysis of DR4, DR5 and FAS receptors at 48 h after transfection and quantiﬁcation of protein bands by densitometric analysis. Data (relative density normalized to actin) represent the
mean with standard deviation (n = 4); #P b 0.005 as compared to Scr-siRNA-transfected cells. (B) Analysis of TRAIL-induced apoptosis by inverted phase contrast microscopy (upper
panels) and ﬂuorescence microscopy (Hoechst 33342 staining, bottom panels). The scale bar represents 25 μm. Images are representative of four independent experiments. (C) Percent-
ages of cells in sub-G0–G1 phase (a) evaluated by ﬂow cytometric analysis of propidium iodide DNA staining, and percentages of early apoptotic cells (b) measured by ﬂow cytometric
analysis of annexin V labelling after TRAIL treatment (1, untransfected cells; 2, cells transfected with Scr-siRNA; 3, cells transfected with p53-siRNA). The data represent the mean with
standard deviation (n = 4). *P b 0.05 and **P b 0.01 as compared to untreated cells. (D) Citoﬂuorimetric analysis by DiOC6 staining of mitochondrial membrane potential (Δψm). The
decrease of ﬂuorescence intensity indicates loss of Δψm. (E) Real-time PCR analysis of Bcl-2 family mRNAs at 48 h after transfection. Data represent the mean with standard deviation
(n = 4); #P b 0.005 as compared to Scr-siRNA-transfected cells. (F) Western blot analysis of Bcl-2 family proteins at 48 h after transfection and quantiﬁcation of protein bands by
densitometric analysis. Data (relative density normalized to actin) represent the mean with standard deviation (n = 4); *P b 0.05 as compared to Scr-siRNA-transfected cells.
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but they were fewer in number and much smaller (mean diameter of
74.9 ± 18.2 μm, containing about 214 cells/sphere). On analyzing
sarcosphere-forming ability through subsequent passages (2° and 3°
spheres), we found (Fig. 7G) that the number of sarcospheres generated
from vector and R248W/P72R cells in each passage remained consistent;
however, R248W/P72R cells formed ~2-fold sarcospheres than vector
cells, demonstrating their higher in vitro self-renewing potential. In addi-
tion, in a colony-forming assay that correlates with self renewal [37],
R248W/P72R cells formed more numerous and larger colonies than vec-
tor cells (Fig. 7H).
We also examined the motility and invasivity of the cells in scratch/
wound healing and in Matrigel transwell invasion assays, respectively.
Comparedwith vector cells, R248W/P72R cells showed highermigratory
(Figs. 8A and 8B) and invasive (Figs. 8C and 8D) activity. These data
suggest that p53-R248W/P72R expression can signiﬁcantly promote
the migratory and invasive function of MG63 cells.
To further determine whether R248W/P72R cells could express
putative cancer stem cell markers, we chose to analyze by ﬂow cytom-
etry the expression proﬁle of two representative stem cell surface
markers of OS, CD133 and ABCG2 [11,35]. As shown in Fig. 8E, the cell
surface expression of CD133 and ABCG2 was very low in both vector
(0.7% and 1.5%, respectively) and R248W/P72R (0.9% and 4.3%, respec-
tively) cells. However, when we analyzed the CD133 and ABCG2 intra-
cellular staining, we found a much higher intracellular positivity in
both vector and R248W/P72R cells. In particular, as shown in Fig. 8F,
R248W/P72R cells express a much higher percentage of CD133-
ABCG2-positivity (24.5% and 88.3%, respectively) than vector cells
(8.3% and 63.1%, respectively). In addition, western blot analyses for
CD133 and ABCG2 show an up-regulation of both markers in R248W/
P72R cells, with an increase of 1.38-fold for CD133 and of 1.25-fold for
ABCG2 with respect to vector cells (Fig. 8G). Furthermore, we investi-
gated, bywestern blot analyses, the proteins regulating andmaintaining
the stem cell phenotype, as Nanog, OCT3/4, nucleostemin (NS) and
Sox2. Interestingly, with respect to vector cells, Nanog, OCT3/4 and NS
were found to signiﬁcantly increase in R248W/P72R cells, with an
increase of 1.56-fold, 1.22-fold and 1.37-fold for Nanog, OCT3/4 and
NS, respectively (Fig. 8G). No signiﬁcant change was observed in Sox2
level.
In the reported experiments, statistically signiﬁcant difference was
not observed in untransfected and vector cells.
Discussion
TP53 mutations occur in almost every type of cancer at rates varying
between 10% in hematopoietic malignancies [38] and 98% in high-grade
serous carcinomaof the ovary [39]. Unlike themajority of tumor suppres-
sor genes, which are inactivated by deletions or truncated mutations,
TP53 mostly undergoes missense mutations [40]. These alterations
produce a full-length mutp53 with a single amino acid substitution that
loses its ability to bind DNA [41], induce apoptosis, inhibit growth and
suppress transformation [42]. Mutp53 is stable, its accumulation is
regarded as a hallmark of cancer [43], and in most cases it not only
loses its tumor-suppressive activities but also gains oncogenic functions
[44]. In OS patients, alterations of TP53 occurs in 50%–60% of cases and
consist of point mutations (20%–30%, mostly missense mutations),
gross gene rearrangements (10%–20%) and allelic loss (75%–80%) [1],
with its mutation status serving as a valuable indicator for predicting
chemoresistance [45]. Accordingly, patients with Li-Fraumeni syndrome,
a disorder characterized by a germline mutation at the p53 locus, have a
signiﬁcantly higher risk of developing OS [46].
In this study, we investigated the TP53 gene status/role of human
3AB-OS CSCs compared with parental MG63 cells. We demonstrated
that in MG63 cells, where TP53 is not expressed and in single copy
[47], the gene does not colocalize on chromosome 17 and is endowed
with a methylated promoter. Instead, 3AB-OS cells strongly express a
p53 protein (p53-R248W/P72R) whose TP53 gene is rearranged and
in multiple copies characterized by P72R polymorphism and hot spot
mutation R248W. It has been reported that TP53 mutations strongly
predominate in exons 4–9 most of which fall within 6 “hotspot” resi-
dues (R175, G245, R248, R249, R273 and R282) in almost all types of
Fig. 5. Effect of p53-R248W/P72R-knockdown on invasive properties of 3AB-OS cells. (A) In vitro invasive capacity of untransfected cells and cells transfectedwith Scr-siRNA or p53-siRNA
through the Matrigel-transwell membranes after 48 h of incubation. Data represent the mean of the percentage of the number of cells relative to untransfected cells with standard devi-
ation (n = 4; *P b 0.05). (B) Real-time PCR analysis of both cell invasion and epithelial-mesenchymal-transition-related genes at 48 h after transfection. Data are the mean with standard
deviation (n = 4); *P b 0.05 and #P b 0.005 as compared to Scr-siRNA-transfected cells. (C) Western blot analysis of both cell invasion and epithelial-mesenchymal-transition-related
proteins at 48 h after transfection; quantiﬁcation of protein bands by densitometric analysis. Data (relative density normalized to actin) represent the mean with standard deviation
(n = 4); *P b 0.05 and #P b 0.005 as compared to Scr-siRNA-transfected cells.
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cancer [48]. Intriguingly, OS patients carrying TP53 hot spot mutations
(most regarding codon 248) were found to have a signiﬁcantly in-
creased death risk [49].
It iswell known thatwild-typep53 is regulated by post-translational
modiﬁcations as phosphorylation at Ser15 (required for its stabilization
[50] and interaction with transcriptional co-activators) and acetylation
at Lys320, 373 and 382 (required for both its transcriptional activity
and its transcription-independent proapoptotic function [51,52]).
Although it has been observed that in UV-induced mouse skin tumors
mutp53 is phosphorylated at Ser15 and accumulated exclusively to
the nucleus [53], up to now little is known about post-translational
modiﬁcations of mutp53 in human OS cell lines or patients. Herein,
we show that in 3AB-OS cells p53-R248W/P72R is constitutively modi-
ﬁed by both phosphorylation at Ser15 and acetylation at Lys320, 373
and 382, and it is localized to the nucleus.
Our results also demonstrated that p53-R248W/P72R-knockdown
strongly reduces the growth and replication rate of 3AB-OS cells and
concomitantly increases the expression of genes, inhibiting cell cycle
progression (pRb, p130, p107, E2F4, GADD45, p21 and p27) while low-
ering CDK4, the activator of the cell cycle progression through G1/S
phase. The ﬁndings are in accordance with alteration of genes involved
in cell cycle seen in up to 80% of pediatric/adult OS patients [54–56],
which demonstrate that genetic lesions deregulating G1/S cell cycle
checkpoint may be a constant feature in the pathogenesis of OS.
Another distinctive feature of mutp53 is its ability to confer on cells
an elevated resistance to a variety of apoptotic signals [44]. Studies
designed to investigate the prognostic signiﬁcance of bax and bcl-2
expression in surgically treated OS patients demonstrate that a
high bax(+)/bcl-2(−) protein expression ratio is associated with
an unfavourable outcome in patients with primary OS, with this
coexpression pattern probably counterbalancing the accelerated prolif-
eration status of themalignant cells and indirectly characterizing amore
aggressive tumor [57]. Moreover, analyses of death receptors in OS
samples and in OS cell lines—among which MG63 cells—demonstrated
alterations only within the DR4 gene, suggesting that these genetic
alterationsmay be implicated in OS formation [58]. We have previously
shown that 3AB-OS cells highly express a great number of genes
required for inhibiting apoptosis [11] and much lower levels of FAS
and DR4 receptors than parental MG63 cells [14]. Here we show that
in 3AB-OS cells p53-R248W/P72R-knockdown potently increases the
expression of DR4 and DR5 receptors and sensitivity to TRAIL-induced
apoptosis. Since, as above reported, DR4 receptor is mutated in parental
MG63 cells, wemaintain that 3AB-OS cells can carry such amutation and
suggest that sensitivity to TRAIL-induced apoptosis in p53-R248W/
P72R-knockdown cells could arise from DR5 receptor up-regulation.
Overall, this ﬁnding, together with the observation that p53-R248W/
P72R-knockdown markedly increased the levels of the proapoptotic
factors Bax and Puma while decreased those of the antiapoptotic factors
Bcl-2 and Bcl-XL, suggests that in 3AB-OS cells p53-R248W/P72R could
hinder cell response to TRAIL-treatment.
Stemness acquisition is a key event in cancer development as it may
induce progression, invasion, dissemination and metastasis. OS is a
highly metastatic tumor with metastases being the major cause of
death, and in patients with high-grade OS, increased MMP expression
was identiﬁed as prognostic marker for poor outcome [59,60]. Herein,
we show that p53-R248W/P72R-knockdown causes a striking reduc-
tion of in vitro invasive capacity of 3AB-OS cells with a decrease of the
invasion-related gene and protein (MMP2, MMP9, ITGα5 and ITGαV)
levels and a concomitant marked increase in E-cadherin. This suggests
that the oncogenic properties of p53-R248W/P72R could also enable
3AB-OS cells to promote invasion.
Recently Sarig et al. [61] reported a novel GOF property for mutp53,
which markedly enhanced the efﬁciency of the reprogramming pro-
cess compared with p53 deﬁciency. This novel activity of mutp53 in-
duced alterations in the characteristics of the reprogrammed cells.
Indeed, although p53-knockout cells reprogrammed with Oct4 and
Sox2 maintained their pluripotent capacity in vivo, reprogrammed
cells expressing mutp53 lost this capacity and gave rise to malignant
tumors.
Since osteosarcomas contain highly proliferative malignant cells
that are largely arrested in their differentiation, OS is proposed to be a
“differentiation-ﬂawed disease,” resulting from genetic and epigenetic
disruption of the osteoblast differentiation pathway [1]. Moreover, the
presence of OS stem-like cells has been reported in patient tumors
[62] aswell as in established humanOS cell lines [63].Wehave previous-
ly shown [11,13,14] that 3AB-OS cells highly express a large panel of
stemness-related genes/proteins and that efﬁciently transdifferentiate
in vitro into cells of all the three primary germ layers [12], whereas
when 3AB-OS cells were engrafted in nude mice, they potently induced
malignant tumors, although preserving multilineage commitment [13].
Here, we show that, after in vitro 3AB-OS differentiation, in each derived
cell lineage, p53-R248W/P72Rwas profoundly down-regulated and after
p53-R248W/P72R-knockdown the expression of pluripotent markers
(Oct3/4, Nanog, Sox2, nucleostemin and CD133)markedly lowered, sug-
gesting that p53-R248W/P72R might be responsible for 3AB-OS cells
pluripotency and self-renewal.
Fig. 6.Effect of p53-R248W/P72R-knockdownonvarious stem-cellmarkers in 3AB-OS cells.
(A) Western blot analysis of p53-R248W/P72R in undifferentiated (U) and differentiated
3AB-OS cells (see below the abbreviations for derived cell lineages) and quantiﬁcation of
protein bands by densitometric analysis. Data (relative density normalized to actin) repre-
sent themeanwith standard deviation (n = 4); **P b 0.01 as compared to undifferentiated
cells. Abbreviations: OD, osteogenic differentiation; AD, adipogenic differentiation; HD,
hepatogenic differentiation; ND, neurogenic differentiation. (B) Western blot analysis of
stemness proteins at 48 h after transfection and quantiﬁcation of protein bands by densito-
metric analysis. The data (relative density normalized to actin) represent the mean with
standard deviation (n = 4); *P b 0.05 and **P b 0.01 as compared to Scr-siRNA-transfected
cells. (C) Real-time PCR analysis of stemness genes at 48 h after transfection.Data represent
the mean with standard deviation (n = 4); *P b 0.05 and #P b 0.005 as compared to Scr-
siRNA-transfected cells.
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Here, we also show that the ectopic expression of p53-R248W/P72R
promotes cancer stem-like properties in osteosarcoma MG63 parental
cells. Indeed, when MG63 cells were transfected with pcDNA3.1-p53-
R248W/P72R, R248W/P72R cells showed strong positivity for p53 and
its nuclear localization. Moreover, R248W/P72R cells, with respect
to vector cells, showed a higher proliferative output, were capable of
forming 2-fold sarcospheres, formedmore numerous and larger colonies
and showed higher migratory and invasive activity. In addition, R248W/
P72R cells showed signiﬁcant increase in the expression of stemness
markers.
In conclusion, the ﬁndings that in 3AB-OS cells p53-R248W/P72R-
knockdown profoundly changed the expression of genes/proteins
correlated to stemness, proliferation, apoptosis and invasiveness, and
that in MG63 parental cells, the ectopic expression of p53-R248W/
Fig. 7. Ectopic expression of p53-R248W/P72R in osteosarcomaMG63 cells and its effect on cell proliferation and sarcosphere- and colony-forming ability. (A)Western blot analysis of p53
inMG63 cells transfectedwith either pcDNA3.1-p53-R248W/P72R (R248W/P72R) or empty pcDNA3.1 vector (vector). Actinwas used as the internal control. Images are representative of
four independent experiments. (B) Cytometric analysis for p53 inR248W/P72R cells. The open histogram indicates isotype control,ﬁlled histogram, indicates the expression of p53. Images
are representative of four independent experiments. (C) Immunoﬂuorescence analysis of p53 in R248W/P72R cells, by double staining cellswith both Hoechst 33342 dye (blue, left panel)
to localize the nucleus and anti-p53 antibody andCy2-conjugated secondary antibody (green,middle panel) to localize p53. In the right panel themerge of the twodyes is shown. The scale
bar represents 25 μm. Images are representative of four independent experiments. (D) Growth curves of vector and R248W/P72R cells. The data represent themean with standard devi-
ation (n = 4); *P b 0.05 and **P b 0.01 as compared to vector cells. (E) Cell cycle distributions in vector and R248W/P72R cells determined using ﬂow cytometry. Results are indicated as
relative percentage of total cell cycle (*P b 0.05, as compared to vector cells). (F) Phase contrast images of primary sarcospheres formed from vector and R248W/P72R cells after 5 and
10 days of culturing. The scale bar represents 50 μm. Graphs summarizing size and number of sarcospheres from 500 cells (on days 5 and 10) and number of cells/sphere on day 10.
The data represent the mean with standard deviation (n = 4); *P b 0.05, **P b 0.01 and #P b 0.005 as compared to vector cells. (G) Graph summarizing numbers of 1°, 2° (generated
from dissociated 1° spheres) and 3° (generated from dissociated 2° spheres) sarcospheres on day 10 from 500 cells. The data represent the mean with standard deviation (n = 4);
*P b 0.05 as compared to vector cells. (H) Clonogenic growth of vector and R248W/P72R cells after 10 days of culturing. Phase contrast images (top; the scale bar represents 200 μm)
and a photograph (bottom) of 6-well plate after staining with methylene blue are shown. Graphs summarizing plate efﬁciency (colonies/100 cells) and relative colony size (mean area
relative to vector cells). The data represent the mean with standard deviation (n = 4); **P b 0.01 and #P b 0.005 as compared to vector cells.
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P72R promoted cancer stem-like properties, suggest that the GOF prop-
erty of p53-R248W/P72R can be at the root of the dedifferentiation
of MG63 cells into 3AB-OS CSCs. We believe that 3AB-OS cells could
provide a best-ﬁt to understand p53-R248W/P72R properties and its
potential involvement in osteosarcomagenesis.
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